Patients O
completed O
the O
SWOG O
Quality O
of O
Life O
Questionnaire O
( O
emotional O
, O
physical O
, O
social O
, O
and O
role O
function O
";" O
general O
symptom O
status O
";" O
treatment/disease-specific O
symptoms O
";" O
and O
global O
HRQL O
[ O
GHRQL O
] O
) O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
annually O
for O
5 O
years O
. O

Erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor-related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Data O
were O
extracted O
from O
the O
database O
of O
a O
prospective O
randomized O
controlled O
trial O
that O
included O
patients O
with O
resectable O
mid O
or O
lower O
thoracic O
esophageal O
cancers O
. O

Similar B-Premise
results I-Premise
were I-Premise
found I-Premise
for I-Premise
low-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
84.3 I-Premise
% I-Premise
) I-Premise
versus I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
87.6 I-Premise
% I-Premise
) I-Premise
or I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
90.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Chemotherapy O
consisted O
of O
intravenous O
( O
i.v O
. O
) O

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+/- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg/d O
or O
matched O
placebo O
. O

For O
this O
randomized O
controlled O
trial O
, O
60 O
patients O
with O
cancer O
were O
recruited O
and O
received O
either O
usual O
care O
or O
the O
intervention O
. O

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

No B-Premise
differences I-Premise
were I-Premise
seen I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
physical I-Premise
and I-Premise
mental I-Premise
component I-Premise
summary I-Premise
scores I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
24 I-Premise
, I-Premise
and I-Premise
36 I-Premise
months I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease-free I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4.4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.81 I-Premise
) I-Premise
. I-Premise

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

A O
planned O
interim O
analysis O
failed O
to O
detect O
an O
RR O
difference O
more O
than O
5 O
% O
. O

a O
15-week O
rehabilitation O
program O
including O
individual O
exercise O
, O
sports O
, O
psycho-education O
, O
and O
information O
. O

A O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O

An B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim

Repeated-measures O
analysis O
of O
variance O
done O
on O
an O
intention O
to O
treat O
basis O
. O

Patients O
completed O
the O
Expanded O
Prostate O
Cancer O
Index O
Composite O
quality-of-life O
questionnaire O
before O
and O
at O
1 O
, O
4 O
, O
8 O
, O
and O
12 O
months O
after O
implantation O
, O
and O
urinary O
domain O
scores O
were O
analyzed O
. O

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

Another O
102 O
patients O
, O
97 O
of O
which O
received O
chemotherapy O
, O
were O
subsequently O
included O
in O
the O
study O
on O
an O
individual O
treatment O
preference O
basis O
. O

Survival B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.70 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
arm I-Premise
. I-Premise

The B-Premise
rates I-Premise
of I-Premise
stroke I-Premise
, I-Premise
pulmonary I-Premise
embolism I-Premise
, I-Premise
and I-Premise
deep-vein I-Premise
thrombosis I-Premise
were I-Premise
elevated I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
these I-Premise
events I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

The B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91.0 I-Premise
% I-Premise
in I-Premise
T4-WD I-Premise
Group I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
in I-Premise
T3-WD I-Premise
Group I-Premise
, I-Premise
and I-Premise
91.3 I-Premise
% I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.2061 I-Premise
) I-Premise
. I-Premise

Vaginal B-Claim
brachytherapy I-Claim
provides I-Claim
a I-Claim
better I-Claim
QOL I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
preferred I-Claim
treatment I-Claim
from I-Claim
a I-Claim
QOL I-Claim
perspective I-Claim
. I-Claim

Patients O
with O
a O
peripheral O
solitary O
lung O
tumor O
( O
NSCLC O
or O
pulmonary O
metastasis O
) O
â‰¤ O
5 O
cm O
were O
eligible O
. O

This B-Claim
is I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
to I-Claim
report I-Claim
that I-Claim
participation I-Claim
in I-Claim
a I-Claim
home I-Claim
walking I-Claim
program I-Claim
confers I-Claim
a I-Claim
significant I-Claim
benefit I-Claim
in I-Claim
resected I-Claim
PPC I-Claim
patients I-Claim
with I-Claim
regard I-Claim
to I-Claim
fatigue I-Claim
levels I-Claim
, I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
and I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Analysis O
was O
by O
intention O
to O
treat O
. O

Clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha-blocker O
, O
age O
, O
IPSS O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
V O
( O
100/200 O
) O
, O
D90 O
, O
and O
time O
to O
obtaining O
a O
normal O
IPSS O
. O

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

HQL O
was O
assessed O
before O
treatment O
initiation O
and O
then O
every O
3 O
weeks O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
Quality O
of O
Life O
Module-Prostate O
14 O
( O
QOLM-P14 O
) O
, O
a O
trial-specific O
module O
developed O
for O
this O
study O
. O

These O
studies O
were O
limited O
by O
a O
lack O
of O
blinding O
and O
absence O
of O
placebo O
controls O
. O

WHO B-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
diarrhoea I-Premise
affected I-Premise
46 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CPT-11 I-Premise
+ I-Premise
LFA I-Premise
5-FU I-Premise
. I-Premise

All O
had O
chemotherapy O
. O

GHS B-Premise
change I-Premise
scores I-Premise
were I-Premise
-0.5 I-Premise
and I-Premise
-7.1 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-3.6 I-Premise
and I-Premise
-15.2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
Grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise

Outcomes O
were O
reassessed O
6 O
and O
12 O
weeks O
after O
chemotherapy O
started O
. O

In O
this O
multicenter O
, O
open-label O
, O
randomized O
phase O
II O
trial O
, O
women O
with O
locally O
advanced O
or O
MBC O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
90 O
mg/m O
( O
2 O
) O
( O
days O
1 O
, O
8 O
, O
15 O
) O
and O
bevacizumab O
10 O
mg/kg O
( O
days O
1 O
, O
15 O
) O
with O
or O
without O
gemcitabine O
1500 O
mg/m O
( O
2 O
) O
( O
days O
1 O
, O
15 O
) O
in O
28-day O
cycles O
. O

Chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
QOL O
outcomes O
. O

Other B-Premise
grade I-Premise
3/4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
rare I-Premise
( I-Premise
< I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Dose-intensified B-Claim
EC I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
CEF I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n=29 O
) O
( O
nutrition O
counseling O
following O
the O
American O
Dietetic O
Association O
[ O
ADA O
] O
medical O
nutrition O
therapy O
[ O
MNT O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n=31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
usual I-Premise
care I-Premise
) I-Premise
for I-Premise
all I-Premise
participants I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
4.6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-27.8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.06 I-Premise
) I-Premise
, I-Premise
and I-Premise
-1.8 I-Premise
( I-Premise
0.81 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Short-term O
, O
in-hospital O
medication O
use O
and O
pain O
levels O
were O
recorded O
. O

Results B-Claim
suggest I-Claim
that I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
fat I-Claim
restriction I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
fat I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
-0.28 I-Claim
) I-Claim
, I-Claim
and I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
F I-Claim
& I-Claim
V I-Claim
consumption I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
daily I-Claim
F I-Claim
& I-Claim
V I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
.11 I-Claim
) I-Claim
. I-Claim

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
noninvasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
50 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
448 O
patients O
were O
enrolled O
over O
a O
period O
of O
3 O
years O
. O

Patients B-Claim
who I-Claim
performed I-Claim
prophylactic I-Claim
swallowing I-Claim
exercises I-Claim
had I-Claim
improved I-Claim
swallowing I-Claim
function I-Claim
at I-Claim
3 I-Claim
and I-Claim
6 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
but I-Claim
not I-Claim
immediately I-Claim
after I-Claim
CRT I-Claim
or I-Claim
at I-Claim
9 I-Claim
and I-Claim
12 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
. I-Claim

Toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30/74 I-Premise
vs. I-Premise
17/92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21/74 I-Premise
vs. I-Premise
13/92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
. I-Premise

Participants O
were O
enrolled O
in O
a O
randomized O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
and O
completed O
outcome O
measures O
prior O
to O
randomization O
. O

All O
patients O
were O
to O
receive O
WBRT O
( O
30 O
Gy O
in O
10 O
fractions O
) O
. O

WHO B-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
occurred I-Premise
in I-Premise
13 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
of I-Premise
experimental I-Premise
arm I-Premise
and I-Premise
in I-Premise
8 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
in I-Premise
control I-Premise
arm I-Premise
. I-Premise

In O
particular O
, O
physical B-Premise
functioning I-Premise
remains I-Premise
deteriorated I-Premise
1 I-Premise
year I-Premise
after I-Premise
inclusion I-Premise
for I-Premise
HDC I-Premise
patients I-Premise
comparatively I-Premise
to I-Premise
conventional I-Premise
chemotherapy I-Premise
patients I-Premise
( I-Premise
85.99 I-Premise
vs. I-Premise
76.65 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
) I-Premise
, O
and B-Premise
the I-Premise
pain I-Premise
score I-Premise
was I-Premise
still I-Premise
higher I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
at I-Premise
that I-Premise
time I-Premise
( I-Premise
28.32 I-Premise
vs. I-Premise
15.97 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

The O
final O
sample O
consisted O
of O
235 O
couples O
: O
123 O
couples O
in O
the O
control O
group O
and O
112 O
couples O
in O
the O
experimental O
group O
. O

The O
trial O
statistician O
and O
researchers O
collecting O
outcome O
measures O
were O
masked O
to O
group O
allocation O
. O

The O
mean O
age O
of O
the O
participants O
was O
58.8 O
years O
";" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O

Irinotecan B-Claim
schedules I-Claim
of I-Claim
weekly I-Claim
and I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
demonstrated I-Claim
similar I-Claim
efficacy I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
FU-refractory I-Claim
, I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
was I-Premise
frequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
febrile I-Premise
neutropenia I-Premise
and I-Premise
infections I-Premise
were I-Premise
more I-Premise
frequent I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
respectively I-Premise
, I-Premise
33 I-Premise
% I-Premise
v I-Premise
10 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
8 I-Premise
% I-Premise
v I-Premise
2 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

Secondary O
endpoints O
were O
the O
PSQI O
component O
scores O
. O

Despite B-Claim
small I-Claim
numbers I-Claim
, I-Claim
the I-Claim
main I-Claim
effect I-Claim
size I-Claim
was I-Claim
robust I-Claim
. I-Claim

Multivariate O
analyses O
were O
used O
to O
evaluate O
the O
association O
of O
the O
genotypes O
on O
the O
four O
endpoints O
. O

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

Anemia B-Claim
is I-Claim
an I-Claim
expected I-Claim
consequence I-Claim
of I-Claim
intensive I-Claim
chemotherapy I-Claim
regimens I-Claim
administered I-Claim
to I-Claim
patients I-Claim
with I-Claim
acute I-Claim
leukemia I-Claim
. I-Claim

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

They O
recorded O
frequency O
, O
duration O
, O
and O
distress O
of O
nausea O
, O
vomiting O
, O
and O
retching O
daily O
, O
beginning O
the O
evening O
of O
chemotherapy O
administration O
and O
continuing O
for O
seven O
days O
. O

Further O
investigation O
in O
larger O
numbers O
of O
patients O
is O
warranted O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

Response B-Premise
rates I-Premise
were I-Premise
34 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
20 I-Premise
% I-Premise
to I-Premise
51 I-Premise
% I-Premise
] I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
20 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

Two O
million O
people O
across O
the O
U.K. O
are O
living O
with O
cancer O
, O
often O
experienced O
as O
a O
long-term O
condition O
. O

Most B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
develop I-Claim
recurrent I-Claim
disease I-Claim
. I-Claim

Patients B-Premise
carrying I-Premise
the I-Premise
GPX1-CC I-Premise
genotype I-Premise
had I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
the I-Premise
UNISCALE I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
OR I-Premise
) I-Premise
: I-Premise
7.5 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
total I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
score I-Premise
( I-Premise
OR I-Premise
: I-Premise
11.0 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
physical I-Premise
( I-Premise
OR I-Premise
: I-Premise
7.1 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
OR I-Premise
: I-Premise
5.2 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
constructs I-Premise
( I-Premise
OR I-Premise
: I-Premise
23.8 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

We O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal O
women O
with O
estrogen O
receptor-positive O
advanced O
breast O
cancer O
who O
experienced O
progression O
after O
prior O
endocrine O
therapy O
. O

Improvement B-Premise
was I-Premise
also I-Premise
found I-Premise
for I-Premise
5-point I-Premise
decrease I-Premise
in I-Premise
PHQ-9 I-Premise
score I-Premise
among I-Premise
72.2 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
compared I-Premise
with I-Premise
59.7 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
OR I-Premise
= I-Premise
1.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.14 I-Premise
to I-Premise
3.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

There B-Claim
is I-Claim
a I-Claim
paucity I-Claim
of I-Claim
high-level I-Claim
evidence I-Claim
on I-Claim
potentially I-Claim
useful I-Claim
interventions I-Claim
and I-Claim
a I-Claim
continued I-Claim
need I-Claim
for I-Claim
new I-Claim
and I-Claim
innovative I-Claim
research I-Claim
, I-Claim
incorporating I-Claim
quality-of-life I-Claim
measurements I-Claim
, I-Claim
in I-Claim
patients I-Claim
experiencing I-Claim
radiation-induced I-Claim
mucositis I-Claim
. I-Claim

Patient O
QOL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
and O
the O
UNISCALE O
QOL O
questionnaires O
. O

The B-Premise
addition I-Premise
of I-Premise
mitoxantrone I-Premise
to I-Premise
prednisone I-Premise
after I-Premise
failure I-Premise
of I-Premise
prednisone I-Premise
alone I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
pain I-Premise
impact I-Premise
, I-Premise
pain I-Premise
relief I-Premise
, I-Premise
insomnia I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

The O
planned O
sample O
size O
was O
850 O
, O
estimated O
to O
result O
in O
334 O
deaths O
, O
which O
would O
provide O
90 O
% O
power O
to O
detect O
a O
difference O
in O
2-year O
survival O
rates O
of O
60 O
% O
v O
70 O
% O
for O
CIS O
versus O
TPZ/CIS O
, O
respectively O
( O
hazard O
ratio O
= O
0.69 O
) O
. O

This O
study O
took O
place O
at O
the O
Royal O
Prince O
Alfred O
Hospital O
, O
Sydney O
, O
Australia O
. O

Twenty-six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
CRT O
. O

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Since O
elderly O
patients O
usually O
have O
several O
concomitant O
diseases O
and O
experience O
more O
treatment O
toxicity O
, O
an O
interim O
safety O
analysis O
was O
planned O
and O
performed O
after O
25 O
patients O
finished O
therapy O
to O
assess O
the O
tolerability O
of O
the O
treatment O
regimens O
. O

Patients O
with O
hormone-refractory O
prostate O
cancer O
and O
a O
history O
of O
bone O
metastases O
were O
randomly O
assigned O
to O
a O
double-blind O
treatment O
regimen O
of O
intravenous O
zoledronic O
acid O
at O
4 O
mg O
( O
N O
= O
214 O
) O
, O
zoledronic O
acid O
at O
8 O
mg O
( O
subsequently O
reduced O
to O
4 O
mg O
";" O
8/4 O
) O
( O
N O
= O
221 O
) O
, O
or O
placebo O
( O
N O
= O
208 O
) O
every O
3 O
weeks O
for O
15 O
months O
. O

The O
original O
analysis O
, O
undertaken O
in O
August O
2003 O
when O
557 O
deaths O
had O
occurred O
, O
showed O
significantly O
better O
survival O
and O
response O
rates O
for O
pain O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
and O
quality O
of O
life O
for O
D3P O
when O
compared O
with O
MP O
. O

Patients B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
in I-Premise
menopausal I-Premise
symptoms I-Premise
but I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.77 I-Premise
) I-Premise
. I-Premise

There O
were O
no O
differences O
between O
treatment O
groups O
in O
dimension O
scores O
at O
baseline O
( O
randomization O
) O
. O

Many O
women O
with O
breast O
cancer O
need O
psychological O
help O
to O
cope O
more O
effectively O
after O
treatment O
. O

Our O
objective O
was O
to O
examine O
the O
effects O
of O
an O
oncologist O
's O
recommendation O
to O
exercise O
on O
self-reported O
exercise O
behavior O
in O
newly O
diagnosed O
breast O
cancer O
survivors O
attending O
their O
first O
adjuvant O
therapy O
consultation O
. O

In O
the O
Asia-Pacific O
region O
and O
elsewhere O
, O
almost O
85 O
% O
of O
patients O
with O
hepatocellular O
carcinoma O
( O
HCC O
) O
are O
inoperable O
at O
diagnosis O
and O
have O
a O
dismal O
prognosis O
. O

To O
assess O
the O
effects O
of O
an O
expressive O
writing O
( O
EW O
) O
intervention O
on O
perceptions O
of O
emotional O
support O
in O
women O
completing O
treatment O
for O
early O
stage O
breast O
cancer O
. O

No B-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
psychological I-Premise
distress I-Premise
. I-Premise

In B-Premise
both I-Premise
groups I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
score I-Premise
peaked I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
decreased I-Premise
thereafter I-Premise
. I-Premise

To O
pilot O
an O
investigation O
of O
individualized O
homeopathy O
for O
symptoms O
of O
estrogen O
withdrawal O
in O
breast O
cancer O
survivors O
. O

Finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
MBAT I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise

The B-Premise
RRs I-Premise
were I-Premise
identical I-Premise
in I-Premise
the I-Premise
2 I-Premise
arms I-Premise
( I-Premise
6.7 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.8-16.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Two B-Premise
patients I-Premise
, I-Premise
1 I-Premise
in I-Premise
each I-Premise
arm I-Premise
, I-Premise
remained I-Premise
in I-Premise
complete I-Premise
remission I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
last I-Premise
follow-up I-Premise
, I-Premise
at I-Premise
45 I-Premise
and I-Premise
38 I-Premise
months I-Premise
from I-Premise
treatment I-Premise
. I-Premise

Randomisation O
was O
stratified O
by O
centre O
. O

Future O
research O
should O
investigate O
ways O
to O
augment O
this O
intervention O
to O
enhance O
its O
benefits O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
. O

Fifty O
four O
patients O
were O
enrolled O
. O

Subgroup O
analyses O
were O
conducted O
to O
identify O
characteristics O
of O
patients O
deriving O
the O
greatest O
clinical O
benefit O
. O

Intraperitoneal B-Claim
perfusion I-Claim
of I-Claim
verapamil I-Claim
enhances I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
chemotherapy I-Claim
drugs I-Claim
, I-Claim
prolongs I-Claim
survival I-Claim
, I-Claim
and I-Claim
improves I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

One O
hundred O
patients O
were O
randomly O
assigned O
to O
undergo O
UAE O
with O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
or O
tris-acryl O
gelatin O
microspheres O
. O

From O
January O
2002 O
to O
February O
2004 O
, O
102 O
patients O
who O
had O
undergone O
RP O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1-those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2-those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3-those O
receiving O
bicalutamide O
and O
RT O
. O

IMRT B-Claim
was I-Claim
significantly I-Claim
better I-Claim
than I-Claim
CRT I-Claim
in I-Claim
terms I-Claim
of I-Claim
parotid I-Claim
sparing I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
for I-Claim
early-stage I-Claim
disease I-Claim
. I-Claim

Progression-free O
survival O
, O
survival O
, O
response O
rate O
, O
safety O
, O
and O
HRQOL O
. O

In O
a O
controlled O
multicentre O
trial O
, O
patients O
were O
randomised O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
chemotherapy O
. O

Fortunately O
, O
cognitive-behavioral O
therapy O
for O
insomnia O
( O
CBT-I O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O

Secondary O
end O
points O
included O
overall O
survival O
, O
response O
rate O
after O
reinitiation O
of O
imatinib O
, O
and O
quality O
of O
life O
. O

Mucositis B-Premise
occurs I-Premise
in I-Premise
almost I-Premise
all I-Premise
patients I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
for I-Premise
head I-Premise
and I-Premise
neck I-Premise
cancer I-Premise
. I-Premise

Both B-Premise
epoetin I-Premise
beta I-Premise
regiments I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
dose-dependent I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
";" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise

We O
describe O
analyses O
of O
data O
for O
patient-reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O

No B-Premise
statistically I-Premise
significant I-Premise
relationships I-Premise
between I-Premise
biomarker I-Premise
expression I-Premise
and I-Premise
outcomes I-Premise
were I-Premise
observed I-Premise
. I-Premise

Adding B-Claim
E I-Claim
to I-Claim
G I-Claim
did I-Claim
not I-Claim
increase I-Claim
hematologic I-Claim
toxicities I-Claim
. I-Claim

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
score I-Premise
from I-Premise
baseline I-Premise
to I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
. I-Premise

Clinical O
follow-up O
was O
obtained O
in O
35 O
patients O
. O

The O
control O
group O
was O
instructed O
to O
perform O
the O
self-management O
treatment O
. O

Survival O
differences O
were O
analyzed O
by O
Wilcoxon O
and O
log-rank O
tests O
. O

The B-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0.16 I-Premise
to I-Premise
2.45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0.66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/t/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

Quality B-Claim
of I-Claim
life I-Claim
during I-Claim
maintenance I-Claim
therapy I-Claim
with I-Claim
pemetrexed I-Claim
is I-Claim
similar I-Claim
to I-Claim
placebo I-Claim
, I-Claim
except B-Claim
for I-Claim
a I-Claim
small I-Claim
increase I-Claim
in I-Claim
loss I-Claim
of I-Claim
appetite I-Claim
, I-Claim
and I-Claim
significantly I-Claim
delayed I-Claim
worsening I-Claim
of I-Claim
pain I-Claim
and I-Claim
haemoptysis I-Claim
. I-Claim

Regimen O
A O
consisted O
of O
PAV O
( O
cisPlatin O
, O
Adriamycin O
, O
VP O
16-213 O
, O
and O
Regimen O
B O
of O
CyMOC O
( O
Cyclophosphamide O
, O
Methotrexate O
, O
Oncovin O
, O
CCNU O
) O
. O

Thus B-Claim
, I-Claim
docetaxel-carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first-line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

No B-Claim
significant I-Claim
differences I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
rate I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
were I-Claim
observed I-Claim
between I-Claim
the I-Claim
two I-Claim
regimen I-Claim
. I-Claim

Compared B-Premise
with I-Premise
their I-Premise
controls I-Premise
, I-Premise
in I-Premise
pamidronate I-Premise
HD/LD I-Premise
patients I-Premise
, I-Premise
events I-Premise
occurred I-Premise
60 I-Premise
% I-Premise
to I-Premise
90 I-Premise
% I-Premise
less I-Premise
frequently I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.03 I-Premise
) I-Premise
and I-Premise
the I-Premise
EFP I-Premise
was I-Premise
prolonged I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Lower B-Claim
dosages I-Claim
of I-Claim
HRT I-Claim
were I-Claim
as I-Claim
effective I-Claim
as I-Claim
higher I-Claim
doses I-Claim
in I-Claim
improving I-Claim
climacteric I-Claim
symptoms I-Claim
and I-Claim
HRQOL I-Claim
ratings I-Claim
and I-Claim
had I-Claim
fewer I-Claim
safety I-Claim
concerns I-Claim
. I-Claim

Moist B-Claim
desquamation I-Claim
was I-Claim
correlated I-Claim
with I-Claim
increased I-Claim
pain I-Claim
and I-Claim
reduction I-Claim
in I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The B-Premise
use I-Premise
of I-Premise
fluoxetine I-Premise
for I-Premise
6 I-Premise
months I-Premise
resulted I-Premise
in I-Premise
an I-Premise
improvement I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
a I-Premise
higher I-Premise
completion I-Premise
of I-Premise
adjuvant I-Premise
treatment I-Premise
( I-Premise
chemotherapy I-Premise
, I-Premise
hormonal I-Premise
therapy I-Premise
, I-Premise
chemotherapy I-Premise
plus I-Premise
hormonal I-Premise
therapy I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
compared I-Premise
to I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
. I-Premise

However B-Premise
, I-Premise
after I-Premise
12 I-Premise
months I-Premise
subscale I-Premise
scores I-Premise
for I-Premise
role-physical I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
, I-Premise
and I-Premise
physical I-Premise
function I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
indicating I-Premise
a I-Premise
better I-Premise
condition I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Using O
a O
single-blinded O
, O
3-armed O
, O
randomized O
controlled O
trial O
, O
450 O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
receive O
an O
oncologist O
exercise O
recommendation O
only O
, O
an O
oncologist O
exercise O
recommendation O
plus O
referral O
to O
an O
exercise O
specialist O
, O
or O
usual O
care O
. O

Median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
CPT-11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
DFS I-Premise
79.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76.4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
OS I-Premise
83.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.925 I-Premise
) I-Premise
. I-Premise

CONNECT O
was O
in O
addition O
to O
standard O
clinical O
follow-up O
. O

This O
non-inferiority O
design O
trial O
aimed O
to O
determine O
whether O
the O
combination O
of O
gemcitabine O
and O
carboplatin O
( O
GC O
) O
results O
in O
similar O
survival O
but O
is O
less O
toxic O
with O
better O
quality O
of O
life O
. O

All O
P O
values O
are O
two-sided O
. O

DC/CIK B-Claim
treatment I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
method I-Claim
for I-Claim
maintenance I-Claim
therapy I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

One O
thousand O
two O
hundred O
ninety-nine O
patients O
were O
randomly O
assigned O
. O

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
EXE I-Premise
( I-Premise
median I-Premise
not I-Premise
reached I-Premise
) I-Premise
than I-Premise
with I-Premise
MA I-Premise
( I-Premise
123.4 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.039 I-Premise
) I-Premise
, I-Premise
as I-Premise
were I-Premise
the I-Premise
median I-Premise
duration I-Premise
of I-Premise
overall I-Premise
success I-Premise
( I-Premise
OR I-Premise
or I-Premise
stable I-Premise
disease I-Premise
> I-Premise
or I-Premise
= I-Premise
24 I-Premise
weeks I-Premise
";" I-Premise
60.1 I-Premise
v I-Premise
49.1 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.025 I-Premise
) I-Premise
, I-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
( I-Premise
20.3 I-Premise
v I-Premise
16.6 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
16.3 I-Premise
v I-Premise
15.7 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.042 I-Premise
) I-Premise
. I-Premise

New B-Claim
fibroid I-Claim
formation I-Claim
is I-Claim
significantly I-Claim
higher I-Claim
after I-Claim
myomectomy I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
ARSR I-Claim
between I-Claim
patients I-Claim
randomised I-Claim
to I-Claim
Calendula I-Claim
or I-Claim
Essex I-Claim
cream I-Claim
was I-Claim
found I-Claim
. I-Claim

Sixty O
female O
breast O
cancer O
survivors O
with O
hot O
flashes O
were O
randomly O
assigned O
to O
receive O
hypnosis O
intervention O
( O
five O
weekly O
sessions O
) O
or O
no O
treatment O
. O

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
QOL I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
Sexual/Relationship I-Claim
Satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim

Attrition O
was O
assessed O
in O
terms O
of O
the O
percent O
of O
participants O
who O
failed O
to O
complete O
these O
assessments O
, O
and O
demographic O
, O
psychiatric O
, O
medical O
, O
and O
study-related O
correlates O
of O
attrition O
were O
examined O
for O
the O
participants O
in O
each O
of O
these O
categories O
. O

Patients B-Premise
on I-Premise
DPPE/DOX I-Premise
arm I-Premise
were I-Premise
significantly I-Premise
worse I-Premise
in I-Premise
terms I-Premise
of I-Premise
average I-Premise
and I-Premise
median I-Premise
pain I-Premise
change I-Premise
scores I-Premise
. I-Premise

A O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer-related O
problems O
and O
to O
improve O
quality O
of O
life O
. O

A O
total O
of O
198 O
women O
continued O
after O
year O
7 O
. O

Psychosocial O
symptoms O
were O
assessed O
with O
the O
use O
of O
a O
self-report O
screening O
instrument O
, O
and O
distressed O
women O
were O
referred O
for O
counseling O
if O
needed O
. O

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
402 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
9.6 I-Premise
months I-Premise
. I-Premise

ORR O
was O
20 O
% O
with O
a O
7.2-month O
median O
response O
duration O
. O

This O
resulted O
in O
a O
higher O
need O
to O
remain O
close O
to O
a O
toilet O
and O
, O
as O
a O
consequence O
, O
more O
limitation O
of O
daily O
activities O
because O
of O
bowel O
symptoms O
and O
decreased O
social O
functioning O
. O

In B-Premise
a I-Premise
multinational I-Premise
trial I-Premise
of I-Premise
anaemic I-Premise
patients I-Premise
with I-Premise
cancer I-Premise
receiving I-Premise
nonplatinum-containing I-Premise
chemotherapy I-Premise
, I-Premise
epoetin-alfa I-Premise
effectively I-Premise
increased I-Premise
haemoglobin I-Premise
levels I-Premise
, I-Premise
reduced I-Premise
red I-Premise
blood I-Premise
cell I-Premise
transfusion I-Premise
requirements I-Premise
, I-Premise
and I-Premise
improved I-Premise
QOL I-Premise
. I-Premise

The O
primary O
outcomes O
-- O
reductions O
in O
various O
dimensions O
of O
distress O
before O
and O
after O
completion O
of O
the O
study O
-- O
were O
measured O
with O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Spiritual O
Well-Being O
Scale O
, O
Patient O
Dignity O
Inventory O
, O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
items O
from O
the O
Structured O
Interview O
for O
Symptoms O
and O
Concerns O
, O
Quality O
of O
Life O
Scale O
, O
and O
modified O
Edmonton O
Symptom O
Assessment O
Scale O
. O

To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

There B-Premise
was I-Premise
a I-Premise
high I-Premise
rate I-Premise
of I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
97 I-Premise
% I-Premise
) I-Premise
but I-Premise
not I-Premise
neutropenic I-Premise
fever I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
during I-Premise
neoadjuvant I-Premise
chemotherapy I-Premise
. I-Premise

The O
present O
study O
showed O
that O
ADT O
with O
the O
gonadotropin O
hormone-releasing O
hormone O
( O
GhRH O
) O
antagonist O
degarelix O
is O
non-inferior O
to O
combined O
treatment O
with O
the O
LHRH O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
BCAA O
granules O
, O
given O
nocturnally O
, O
in O
improving O
QOL O
in O
these O
patients O
. O

Participants O
were O
randomly O
assigned O
to O
receive O
a O
10-month O
program O
of O
mailed O
print O
materials O
on O
diet O
and O
PA O
available O
in O
the O
public O
domain O
or O
a O
10-month O
program O
of O
tailored O
materials O
designed O
to O
increase O
fruit O
and O
vegetable O
( O
F O
& O
V O
) O
intake O
, O
decrease O
fat O
intake O
, O
and/or O
increase O
PA. O
Changes O
in O
self-efficacy O
for O
F O
& O
V O
intake O
and O
fat O
restriction O
were O
analyzed O
as O
potential O
mediators O
of O
the O
intervention O
's O
effects O
on O
diet O
at O
2-year O
follow-up O
. O

Unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane-based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise

Main O
exclusion O
criteria O
were O
brain O
or O
bone O
metastases O
. O

A O
randomized O
controlled O
trial O
was O
conducted O
in O
cooperation O
with O
the O
Departments O
of O
General O
Surgery O
and O
Medical O
Psychology O
, O
University O
Hospital O
of O
Hamburg O
, O
Germany O
, O
from O
January O
1991 O
to O
January O
1993 O
. O

The B-Premise
Breast I-Premise
Cancer I-Premise
Subscale I-Premise
scores I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
group I-Premise
C I-Premise
patients I-Premise
( I-Premise
p=0.021 I-Premise
) I-Premise
. I-Premise

The O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
CACS O
utilizing O
megestrol O
acetate O
( O
MA O
) O
plus O
thalidomide O
. O

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
KP I-Premise
from I-Premise
baseline I-Premise
to I-Premise
pre-cycle I-Premise
3 I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
3w4 I-Premise
regimen I-Premise
for I-Premise
duration I-Premise
and I-Premise
faster I-Premise
onset I-Premise
of I-Premise
improvement I-Premise
. I-Premise

Patients O
in O
the O
single-agent O
arm O
( O
n O
= O
153 O
) O
received O
weekly O
epirubicin O
( O
E O
) O
20 O
mg/m2 O
until O
progression O
or O
until O
the O
cumulative O
dose O
of O
1,000 O
mg/m2 O
, O
followed O
by O
mitomycin O
( O
M O
) O
8 O
mg/m2 O
every O
4 O
weeks O
, O
and O
those O
in O
the O
combination O
chemotherapy O
arm O
( O
n O
= O
150 O
) O
were O
first O
given O
cyclophosphamide O
500 O
mg/m2 O
, O
E O
60 O
mg/m2 O
, O
and O
fluorouracil O
500 O
mg/m2 O
three O
times O
per O
week O
( O
CEF O
) O
followed O
by O
M O
8 O
mg/m2 O
plus O
vinblastine O
( O
V O
) O
6 O
mg/m2 O
every O
4 O
weeks O
. O

Therapy O
for O
polycystic O
liver O
is O
invasive O
, O
expensive O
, O
and O
has O
disappointing O
long-term O
results O
. O

Numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
10.6 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.67 I-Premise
) I-Premise
, I-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
13.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
14.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.98 I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
26.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
23.4 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.60 I-Premise
) I-Premise
. I-Premise

The O
mean O
follow-up O
period O
was O
53.6 O
months O
. O

We O
performed O
a O
4-arm O
randomised O
trial O
to O
compare O
( O
1 O
) O
a O
low-dose O
intravenous O
bolus O
of O
LV O
( O
20 O
mg/m2 O
) O
, O
followed O
by O
an O
intravenous O
bolus O
of O
5FU O
( O
400 O
mg/m2 O
) O
, O
followed O
by O
a O
22-hour O
continuous O
infusion O
of O
5FU O
( O
600 O
mg/m2 O
) O
on O
day O
1 O
and O
day O
2/2 O
weeks O
( O
ldLV5FU2 O
arm O
) O
, O
( O
2 O
) O
a O
weekly O
continuous O
infusion O
of O
high-dose O
5FU O
( O
2.6 O
g/m2/week O
) O
for O
6 O
weeks O
followed O
by O
a O
rest O
week O
( O
HD-FU O
arm O
) O
and O
( O
3 O
) O
raltitrexed O
( O
Tomudex O
arm O
";" O
3 O
mg/m2/3 O
weeks O
) O
to O
standard O
LV5FU2 O
. O

55.6 B-Premise
% I-Premise
patients I-Premise
treated I-Premise
over I-Premise
4 I-Premise
days I-Premise
and I-Premise
33.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
over I-Premise
11 I-Premise
days I-Premise
experienced I-Premise
acute I-Premise
grade I-Premise
â‰¥ I-Premise
2 I-Premise
toxicity I-Premise
( I-Premise
p=0.085 I-Premise
) I-Premise
. I-Premise

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

The O
sample O
size O
required O
in O
a O
larger O
definitive O
study O
is O
32 O
subjects O
per O
group O
. O

Despite B-Claim
side I-Claim
effects I-Claim
resulting I-Claim
from I-Claim
administration I-Claim
of I-Claim
tamoxifen I-Claim
, I-Claim
its I-Claim
use I-Claim
as I-Claim
a I-Claim
breast I-Claim
cancer I-Claim
preventive I-Claim
agent I-Claim
is I-Claim
appropriate I-Claim
in I-Claim
many I-Claim
women I-Claim
at I-Claim
increased I-Claim
risk I-Claim
for I-Claim
the I-Claim
disease I-Claim
. I-Claim

To O
compare O
short- O
and O
long-term O
effects O
of O
adjuvant O
treatment O
versus O
observation O
after O
surgery O
on O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
prostate O
cancer O
patients O
. O

Long-term B-Premise
benefits I-Premise
for I-Premise
older I-Premise
patients I-Premise
were I-Premise
seen I-Premise
in I-Premise
the I-Premise
anger-hostility I-Premise
scale I-Premise
at I-Premise
week I-Premise
27 I-Premise
( I-Premise
92.2 I-Premise
vs. I-Premise
84.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.027 I-Premise
) I-Premise
and I-Premise
week I-Premise
52 I-Premise
( I-Premise
96.3 I-Premise
vs. I-Premise
85.9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
. I-Premise

With B-Premise
regard I-Premise
to I-Premise
the I-Premise
long-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

This B-Premise
translated I-Premise
into I-Premise
a I-Premise
lower I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
moist I-Premise
desquamation I-Premise
during I-Premise
or I-Premise
up I-Premise
to I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
their I-Premise
radiation I-Premise
treatment I-Premise
";" I-Premise
31.2 I-Premise
% I-Premise
with I-Premise
IMRT I-Premise
compared I-Premise
with I-Premise
47.8 I-Premise
% I-Premise
with I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
0.2-13.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

Enzastaurin O
( O
E O
) O
inhibits O
PKCÎ² O
and O
PI3K/AKT O
signaling O
pathways O
with O
a O
dose-dependent O
effect O
on O
growth O
of O
pancreatic O
carcinoma O
xenografts O
. O

CAF B-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
leukopenia I-Premise
, I-Premise
granulocytopenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
liver I-Premise
and I-Premise
cardiac I-Premise
toxicity I-Premise
, I-Premise
whereas O
the B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
weight I-Premise
loss I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
skin I-Premise
and I-Premise
neurotoxicity I-Premise
. I-Premise

Mixed-effects O
models O
and O
multivariate O
regressions O
were O
used O
to O
examine O
the O
longitudinal O
impact O
of O
the O
intervention O
on O
patient-physician O
communication O
, O
dynamics O
of O
patient-physician O
interaction O
, O
and O
the O
association O
between O
PROs O
and O
the O
content O
of O
clinic O
discussion O
. O

Because O
we O
previously O
found O
that O
change O
in O
self-efficacy O
for O
PA O
did O
not O
vary O
by O
group O
assignment O
, O
the O
relationship O
between O
change O
in O
self-efficacy O
and O
PA O
at O
2-year O
follow-up O
was O
examined O
across O
study O
conditions O
. O

Palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O

Improvement B-Premise
in I-Premise
physical I-Premise
functioning I-Premise
correlated I-Premise
positively I-Premise
with I-Premise
weight I-Premise
gain I-Premise
( I-Premise
r I-Premise
= I-Premise
0.56 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The O
World O
Health O
Organization O
( O
WHO O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first-line O
therapy O
, O
so-called O
" O
weak O
" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second-line O
therapy O
, O
and O
so-called O
" O
strong O
" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third-line O
therapy O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
either I-Premise
PFS I-Premise
or I-Premise
OS I-Premise
between I-Premise
IFN1 I-Premise
and I-Premise
IFN5 I-Premise
( I-Premise
median I-Premise
of I-Premise
3.7 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
3.4 I-Premise
months I-Premise
PFS I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
of I-Premise
25.5 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
17.5 I-Premise
months I-Premise
OS I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The O
primary O
endpoint O
is O
toxicity O
, O
and O
secondary O
endpoints O
include O
response O
rate O
, O
survival O
outcome O
and O
quality O
of O
life O
( O
QOL O
) O
. O

To O
compare O
dose-volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
IUS/EUS O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O

Patients B-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
EEP-L I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise

Dose B-Premise
intensities I-Premise
of I-Premise
concurrent I-Premise
cisplatin I-Premise
, I-Premise
late I-Premise
RT I-Premise
toxicities I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
were I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Of O
the O
186 O
total O
patients O
, O
113 O
had O
initial O
treatment O
with O
platinum O
therapy O
and O
DNA O
samples O
of O
whom O
46 O
also O
had O
QOL O
data O
. O

In O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
London O
, O
UK O
, O
who O
had O
problematic O
HFNS O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast-cancer O
treatment O
. O

Health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O

Differences B-Premise
were I-Premise
significant I-Premise
between I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
OR I-Premise
0.12 I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
groups I-Premise
1 I-Premise
and I-Premise
3 I-Premise
( I-Premise
OR I-Premise
0.52 I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Claim
patient I-Claim
accrual I-Claim
to I-Claim
this I-Claim
trial I-Claim
made I-Claim
its I-Claim
results I-Claim
inconclusive I-Claim
, I-Claim
but O
several O
observations O
are O
notable O
. O

The O
purpose O
of O
this O
analysis O
was O
to O
assess O
the O
impact O
of O
pretreatment O
factors O
on O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
locally O
advanced O
nonsmall O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
quality O
of O
life O
( O
QOL O
) O
of O
high-risk O
breast O
cancer O
patients O
included O
in O
a O
randomized O
clinical O
trial O
( O
PEGASE O
1 O
) O
comparing O
conventional O
chemotherapy O
versus O
adding O
an O
additional O
high-dose O
chemotherapy O
( O
HDC O
) O
cycle O
with O
blood O
stem O
cell O
support O
. O

Seventy-two O
patients O
who O
underwent O
surgery O
for O
lung O
( O
n=27 O
) O
or O
gastrointestinal O
tumours O
( O
n=42 O
) O
were O
assigned O
to O
an O
aerobic O
exercise O
group O
( O
stationary O
biking O
30 O
min O
five O
times O
weekly O
) O
or O
a O
progressive O
relaxation O
training O
group O
( O
45 O
min O
three O
times O
per O
week O
) O
. O

Nocturnal O
administration O
of O
branched-chain O
amino O
acid O
( O
BCAA O
) O
granules O
improves O
serum O
albumin O
levels O
in O
patients O
with O
cirrhosis O
. O

From O
1997 O
to O
2001 O
, O
294 O
patients O
were O
included O
. O

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

Findings B-Claim
suggest I-Claim
that I-Claim
self-efficacy I-Claim
may I-Claim
influence I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Results B-Premise
showed I-Premise
overall I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
psychosocial I-Premise
stress I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
in I-Premise
both I-Premise
the I-Premise
MBAT I-Premise
and I-Premise
educational I-Premise
support I-Premise
groups I-Premise
immediately I-Premise
post-intervention I-Premise
";" I-Premise
however B-Premise
, I-Premise
participants I-Premise
with I-Premise
high I-Premise
stress I-Premise
levels I-Premise
at I-Premise
baseline I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
overall I-Premise
outcomes I-Premise
only I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
group I-Premise
, I-Premise
both I-Premise
immediately I-Premise
post-intervention I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

An O
alpha-blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy-related O
urinary O
morbidity O
. O

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25Â·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23Â·0-27Â·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27Â·1 I-Premise
months I-Premise
( I-Premise
22Â·8-30Â·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

We O
performed O
a O
prospective O
randomized O
phase O
III O
study O
to O
examine O
whether O
sequential O
administration O
of O
topotecan O
can O
improve O
the O
efficacy O
of O
carboplatin O
and O
paclitaxel O
in O
first-line O
treatment O
of O
advanced O
epithelial O
ovarian O
cancer O
. O

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

A B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
> I-Premise
or=2 I-Premise
g/dL I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30,000 I-Premise
IU I-Premise
and I-Premise
66.7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20,000 I-Premise
IU I-Premise
. I-Premise

We O
carried O
out O
a O
randomized O
phase O
II O
trial O
to O
select O
one O
of O
the O
following O
treatment O
regimens O
for O
further O
investigation O
: O
weekly O
irinotecan O
at O
a O
dose O
of O
70 O
mg/m O
( O
2 O
) O
days O
1 O
, O
8 O
, O
15 O
, O
22 O
, O
29 O
( O
arm O
A O
) O
or O
3-weekly O
irinotecan O
at O
a O
dose O
of O
300/240 O
mg/m O
( O
2 O
) O
day O
1 O
and O
days O
22 O
( O
arm O
B O
) O
in O
combination O
with O
capecitabine O
1000 O
mg/m O
( O
2 O
) O
twice O
daily O
days O
1-14 O
and O
days O
22-35 O
every O
6 O
weeks O
. O

We O
assessed O
whether O
minimally O
invasive O
oesophagectomy O
reduces O
morbidity O
compared O
with O
open O
oesophagectomy O
. O

Survival O
duration O
, O
disease-free O
survival O
, O
quality O
of O
life O
and O
costs O
were O
evaluated O
separately O
. O

Patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Patients O
with O
sentinel O
lymph O
node O
metastases O
proceeded O
to O
delayed O
axillary O
clearance O
or O
received O
axillary O
radiotherapy O
( O
depending O
on O
the O
protocol O
at O
the O
treating O
institution O
) O
. O

Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

IFNalpha O
was O
administered O
three O
times O
a O
week O
at O
a O
dose O
of O
3 O
million O
units O
subcutaneously O
for O
24 O
months O
. O

Radiation-induced O
mucositis O
is O
an O
acute O
reaction O
of O
the O
mucosa O
of O
patients O
undergoing O
head O
and O
neck O
radiotherapy O
. O

Follow-up O
examinations O
were O
performed O
12 O
months O
after O
ablation O
to O
assess O
ablation O
outcome O
in O
each O
group O
by O
131 O
whole O
body O
scans O
( O
WBSs O
) O
, O
serum O
thyroglobulin O
measurement O
after O
TSH O
stimulation O
, O
and O
neck O
ultrasonography O
. O

The O
most O
likely O
advantage O
of O
LRP O
is O
the O
superior O
cosmetic O
result O
. O

Embolization O
was O
performed O
in O
a O
standardized O
manner O
. O

Hospital O
anxiety O
and O
depression O
scale O
scores O
were O
consistent O
with O
the O
primary O
outcome O
measure O
. O

Significant B-Premise
group I-Premise
by I-Premise
time I-Premise
interactions I-Premise
showed I-Premise
that I-Premise
there I-Premise
was I-Premise
an I-Premise
improvement I-Premise
in I-Premise
dyads I-Premise
' I-Premise
coping I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
self-efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
social I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
in I-Premise
caregivers I-Premise
' I-Premise
emotional I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rate I-Premise
was I-Premise
higher I-Premise
with I-Premise
DCF I-Premise
( I-Premise
chi2 I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Cancer O
cells O
rely O
on O
angiogenesis O
for O
growth O
and O
dissemination O
, O
and O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
is O
a O
highly O
angiogenic O
tumor O
. O

Adverse B-Premise
events I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
. I-Premise

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

All O
patients O
were O
randomized O
to O
receive O
half O
of O
a O
sachet O
of O
imiquimod O
5 O
% O
cream O
twice O
weekly O
on O
half O
of O
their O
face O
and O
two O
sessions O
of O
PDT O
with O
20 O
% O
solution O
of O
ALA O
applied O
for O
1 O
hour O
to O
the O
other O
side O
of O
the O
face O
. O

Complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
DCF I-Premise
than I-Premise
CF I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

General O
practices O
in O
UK O
( O
384 O
) O
, O
Australia O
( O
91 O
) O
, O
and O
New O
Zealand O
( O
24 O
) O
. O

Quality-of-life B-Premise
scores I-Premise
for I-Premise
physical I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
perceived I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
.043 I-Premise
) I-Premise
decreased I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
control I-Premise
group I-Premise
but I-Premise
for I-Premise
not I-Premise
the I-Premise
HBO I-Premise
group I-Premise
. I-Premise

After O
stratification O
by O
estrogen O
receptor O
( O
ER O
) O
status O
, O
patients O
were O
randomly O
assigned O
to O
receive O
three O
28-day O
courses O
of O
" O
classical O
" O
adjuvant O
CMF O
chemotherapy O
( O
cyclophosphamide O
at O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-14 O
, O
orally O
";" O
methotrexate O
at O
40 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
";" O
and O
5-fluorouracil O
at O
600 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
) O
followed O
by O
tamoxifen O
( O
20 O
mg/day O
, O
orally O
for O
57 O
months O
) O
( O
CMF O
-- O
> O
tamoxifen O
) O
or O
to O
receive O
tamoxifen O
alone O
( O
20 O
mg/day O
, O
orally O
for O
60 O
months O
) O
. O

Safety O
was O
also O
assessed O
. O

Multivariate B-Premise
analysis I-Premise
showed I-Premise
a I-Premise
significant I-Premise
impact I-Premise
of I-Premise
duration I-Premise
of I-Premise
response/CR I-Premise
on I-Premise
improving I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
pain I-Premise
, I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
scores I-Premise
. I-Premise

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
a O
family-based O
intervention O
could O
improve O
appraisal O
variables O
( O
appraisal O
of O
illness O
or O
caregiving O
, O
uncertainty O
, O
hopelessness O
) O
, O
coping O
resources O
( O
coping O
strategies O
, O
self-efficacy O
, O
communication O
) O
, O
symptom O
distress O
, O
and O
quality O
of O
life O
in O
men O
with O
prostate O
cancer O
and O
their O
spouses O
. O

Both B-Premise
brief I-Premise
and I-Premise
extensive I-Premise
programs I-Premise
had I-Premise
positive I-Premise
outcomes I-Premise
for I-Premise
patient-caregiver I-Premise
dyads I-Premise
, I-Premise
but B-Premise
few I-Premise
sustained I-Premise
effects I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
was I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

To O
evaluate O
the O
impact O
of O
letrozole O
compared O
with O
placebo O
after O
adjuvant O
tamoxifen O
on O
quality O
of O
life O
( O
QOL O
) O
in O
the O
MA.17 O
trial O
. O

To O
assess O
the O
safety O
and O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
continuous O
combined O
hormone O
replacement O
therapy O
( O
ccHRT O
) O
with O
estradiol O
valerate/medroxyprogesterone O
acetate O
( O
E O
( O
2 O
) O
V/MPA O
) O
over O
nine O
years O
and O
at O
follow-up O
one O
year O
after O
discontinuation O
. O

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
with I-Premise
pamidronate I-Premise
and I-Premise
deteriorated I-Premise
after I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study-related I-Premise
variables I-Premise
. I-Premise

The B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
QLQ-C30 I-Premise
questionnaire I-Premise
and I-Premise
LC30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Four O
weeks O
of O
therapy O
constituted O
1 O
cycle O
";" O
patients O
could O
receive O
up O
to O
8 O
cycles O
and O
those O
who O
completed O
8 O
cycles O
were O
given O
the O
option O
of O
receiving O
extended O
therapy O
. O

Participants B-Premise
completing I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
improvement I-Premise
in I-Premise
male I-Premise
overall I-Premise
distress I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
male I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
female I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
, I-Premise
but B-Premise
regression I-Premise
toward I-Premise
baseline I-Premise
was I-Premise
noted I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

Radiation B-Claim
therapy I-Claim
for I-Claim
prostate I-Claim
carcinoma I-Claim
causes I-Claim
persistent I-Claim
GI I-Claim
toxicity I-Claim
that I-Claim
is I-Claim
largely I-Claim
independent I-Claim
of I-Claim
the I-Claim
two I-Claim
dose I-Claim
schedules I-Claim
. I-Claim

Patients O
aged O
> O
65 O
years O
with O
newly O
diagnosed O
MM O
were O
randomized O
to O
receive O
melphalan O
plus O
prednisone O
( O
MP O
) O
or O
MPT O
, O
followed O
by O
thalidomide O
maintenance O
in O
the O
MPT O
arm O
. O

The O
primary O
outcome O
measure O
was O
survival O
. O

Arm O
circumferences O
were O
measured O
before O
and O
the O
1st O
, O
3rd O
, O
and O
6th O
weeks O
of O
the O
treatment O
. O

The B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

A O
total O
of O
60 O
patients O
were O
enrolled O
: O
41 O
patients O
diagnosed O
with O
resectable O
and O
19 O
patients O
diagnosed O
with O
unresectable O
pancreatic O
cancer O
. O

There B-Claim
is I-Claim
a I-Claim
need I-Claim
for I-Claim
further I-Claim
studies I-Claim
so I-Claim
that I-Claim
its I-Claim
effect I-Claim
can I-Claim
be I-Claim
confirmed I-Claim
. I-Claim

The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
effect O
of O
combined O
treatment O
methods O
on O
quality O
of O
life O
in O
patients O
diagnosed O
with O
pancreatic O
cancer O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
with I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
versus I-Premise
5 I-Premise
% I-Premise
";" I-Premise
p=0.0025 I-Premise
) I-Premise
. I-Premise

Low-frequency B-Premise
low-intensity I-Premise
electrotherapy I-Premise
did I-Premise
not I-Premise
reduce I-Premise
lymphoedema I-Premise
volume I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
19.77 I-Premise
mL I-Premise
, I-Premise
P I-Premise
= I-Premise
0.36 I-Premise
) I-Premise
, I-Premise
but O
significant B-Premise
reductions I-Premise
were I-Premise
observed I-Premise
in I-Premise
pain I-Premise
, I-Premise
heaviness I-Premise
and I-Premise
tightness I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
13.1 I-Premise
, I-Premise
16.2 I-Premise
and I-Premise
6.4 I-Premise
mm I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
FACT-B+4 I-Premise
summaries I-Premise
improved I-Premise
significantly I-Premise
( I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
5.4 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.015 I-Premise
) I-Premise
. I-Premise

The O
objective O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
systematic O
feedback O
from O
standardized O
assessment O
tools O
for O
hospice O
patient-caregiver O
dyads O
in O
improving O
hospice O
outcomes O
compared O
with O
the O
usual O
clinical O
practice O
. O

Mean B-Premise
depression I-Premise
scores I-Premise
fell I-Premise
from I-Premise
6.7 I-Premise
to I-Premise
3.6 I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
6.1 I-Premise
to I-Premise
5.4 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
14.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Baseline O
FACT-H O
& O
amp O
";" O
N O
data O
were O
available O
for O
1,093 O
patients O
and O
missing O
for O
417 O
patients O
. O

Response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175-mg/m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg/m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.2 I-Premise
) I-Premise
. I-Premise

Docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

This O
study O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
nurse-delivered O
telephone O
supportive O
intervention O
( O
the O
" O
CONNECT O
" O
intervention O
) O
. O

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

After B-Premise
a I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93-46-53 O
( O
INT O
146 O
) O
. O

We O
aimed O
at O
investigating O
the O
efficacy O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
QOL O
) O
of O
gemcitabine O
( O
GEM O
) O
compared O
with O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
in O
the O
salvage O
treatment O
of O
recurrent O
ovarian O
cancer O
. O

In B-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
, I-Premise
ORR I-Premise
was I-Premise
17.3 I-Premise
% I-Premise
( I-Premise
4/23 I-Premise
) I-Premise
, I-Premise
DCR I-Premise
was I-Premise
39.1 I-Premise
% I-Premise
( I-Premise
9/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
was I-Premise
4.4 I-Premise
months I-Premise
. I-Premise

Four O
hundred O
forty-five O
patients O
randomly O
received O
either O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
each O
on O
day O
1 O
plus O
fluorouracil O
750 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
3 O
weeks O
( O
DCF O
) O
or O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
plus O
fluorouracil O
1,000 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
4 O
weeks O
( O
CF O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
adverse I-Premise
effects I-Premise
associated I-Premise
with I-Premise
r-HuEPO I-Premise
. I-Premise

The O
two O
arms O
were O
well O
balanced O
for O
relevant O
patient O
and O
disease O
characteristics O
. O

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first-generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Study O
objectives O
included O
response O
( O
primary O
) O
, O
survival O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

For O
NSCLC O
lung O
tumors O
â‰¤ O
3 O
cm O
, O
a O
dose O
of O
48 O
Gy O
in O
4 O
fractions O
was O
used O
, O
otherwise O
52 O
Gy O
in O
4 O
fractions O
was O
delivered O
. O

Patients O
with O
untreated O
stage O
IC-IV O
ovarian O
cancer O
received O
six O
cycles O
of O
carboplatin O
area O
under O
the O
curve O
6 O
( O
AUC O
6 O
) O
3 O
weekly O
either O
with O
no O
dose O
modification O
except O
for O
toxicity O
( O
Arm O
A O
) O
or O
with O
dose O
escalations O
in O
cycles O
2-6 O
based O
on O
nadir O
neutrophil O
and O
platelet O
counts O
( O
Arm O
B O
) O
. O

Although B-Premise
the I-Premise
CR/PR I-Premise
and I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
groups I-Premise
had I-Premise
similar I-Premise
times I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
, I-Premise
patients B-Claim
with I-Claim
CR/PR I-Claim
reported I-Claim
better I-Claim
QL I-Claim
, I-Claim
suggesting I-Claim
more I-Claim
beneficial I-Claim
response I-Claim
to I-Claim
second-line I-Claim
endocrine I-Claim
treatment I-Claim
. I-Claim

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
4.7 I-Premise
months I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
5.3 I-Premise
months I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Post O
hoc O
analysis O
by O
KRAS O
mutation O
status O
was O
performed O
. O

r-HuEPO B-Claim
is I-Claim
safe I-Claim
and I-Claim
can I-Claim
cause I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
the I-Claim
hematocrit I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
myelosuppressive I-Claim
, I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
role I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
in I-Claim
postmenopausal I-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node-negative I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
controversial I-Claim
. I-Claim

No B-Premise
statistical I-Premise
significance I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
FACT-G I-Premise
scores I-Premise
and I-Premise
FACT-B I-Premise
scores I-Premise
among I-Premise
different I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
week I-Premise
4 I-Premise
, I-Premise
week I-Premise
8 I-Premise
and I-Premise
week I-Premise
12 I-Premise
after I-Premise
NHT I-Premise
. I-Premise

One O
hundred O
ninety-five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O

Dignity O
therapy O
is O
a O
unique O
, O
individualised O
, O
short-term O
psychotherapy O
that O
was O
developed O
for O
patients O
( O
and O
their O
families O
) O
living O
with O
life-threatening O
or O
life-limiting O
illness O
. O

The B-Claim
combination I-Claim
of I-Claim
interferon I-Claim
alfa I-Claim
( I-Claim
IFNalpha I-Claim
) I-Claim
and I-Claim
isotretinoin I-Claim
has I-Claim
shown I-Claim
a I-Claim
direct I-Claim
antiproliferative I-Claim
effect I-Claim
on I-Claim
human I-Claim
melanoma I-Claim
cell I-Claim
lines I-Claim
, I-Claim
but B-Claim
it I-Claim
remained I-Claim
unclear I-Claim
whether I-Claim
this I-Claim
combination I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
IFNalpha I-Claim
alone I-Claim
in I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
melanoma I-Claim
. I-Claim

Based B-Premise
on I-Premise
serum I-Premise
rhTSH-stimulated I-Premise
Tg I-Premise
alone I-Premise
( I-Premise
Tg I-Premise
< I-Premise
0.8 I-Premise
microg/l I-Premise
, I-Premise
BRAHMS I-Premise
Tg I-Premise
Kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
ablation I-Premise
success I-Premise
was I-Premise
observed I-Premise
between I-Premise
rhTSH I-Premise
and I-Premise
hypothyroidism I-Premise
groups I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
and I-Premise
97.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
had I-Premise
an I-Premise
improvement I-Premise
in I-Premise
fatigue I-Premise
as I-Premise
shown I-Premise
by I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
BFI I-Premise
global I-Premise
score I-Premise
( I-Premise
-0.66 I-Premise
points I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1.04 I-Premise
to I-Premise
-0.27 I-Premise
) I-Premise
and I-Premise
FSS I-Premise
total I-Premise
score I-Premise
( I-Premise
-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.78 I-Premise
to I-Premise
-0.21 I-Premise
) I-Premise
. I-Premise

All O
complications O
were O
recorded O
, O
and O
these O
preoperative O
assessments O
were O
repeated O
at O
4 O
months O
. O

Psychosocial B-Claim
intervention I-Claim
is I-Claim
a I-Claim
cost-effective I-Claim
approach I-Claim
that I-Claim
can I-Claim
improve I-Claim
a I-Claim
patient I-Claim
's I-Claim
mood I-Claim
and I-Claim
QOL I-Claim
both I-Claim
during I-Claim
and I-Claim
after I-Claim
RT I-Claim
. I-Claim

Testosterone O
kinetics O
and O
QOL O
were O
also O
evaluated O
. O

Maintenance B-Premise
therapy I-Premise
with I-Premise
erlotinib I-Premise
did I-Premise
not I-Premise
impact I-Premise
on I-Premise
deterioration I-Premise
in I-Premise
HRQoL I-Premise
: I-Premise
TSP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
=0.91 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.74-1.12 I-Premise
] I-Premise
";" I-Premise
n=785 I-Premise
) I-Premise
, I-Premise
TTD I-Premise
in I-Premise
TOI I-Premise
( I-Premise
HR=1.06 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.87-1.31 I-Premise
] I-Premise
";" I-Premise
n=781 I-Premise
) I-Premise
and I-Premise
TTD I-Premise
in I-Premise
HRQoL I-Premise
( I-Premise
HR=0.96 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.79-1.16 I-Premise
] I-Premise
";" I-Premise
n=776 I-Premise
) I-Premise
. I-Premise

Systemic B-Premise
recurrence I-Premise
was I-Premise
7/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
9.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
5/92 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Seventy-six O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
were O
randomized O
to O
receive O
the O
study O
drug O
either O
once O
( O
n O
= O
30 O
) O
or O
3 O
times O
weekly O
( O
n O
= O
46 O
) O
. O

The B-Claim
TAX I-Claim
326 I-Claim
study I-Claim
shows I-Claim
that I-Claim
docetaxel-platinum I-Claim
regimens I-Claim
relieve I-Claim
symptoms I-Claim
and I-Claim
improve I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim

Gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
OS I-Premise
compared I-Premise
with I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.932 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.716 I-Premise
to I-Premise
1.213 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.604 I-Premise
";" I-Premise
median I-Premise
OS I-Premise
, I-Premise
22.3 I-Premise
v I-Premise
22.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Analyses O
were O
done O
on O
all O
patients O
with O
available O
data O
at O
baseline O
and O
at O
the O
end O
of O
the O
study O
intervention O
. O

The B-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
for I-Premise
PSA I-Premise
nadir I-Premise
â‰¤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
and I-Premise
> I-Premise
0.2 I-Premise
to I-Premise
4 I-Premise
ng/ml I-Premise
in I-Premise
CAD I-Premise
was I-Premise
31 I-Premise
% I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
primary O
end-point O
was O
acute O
grade O
â‰¥ O
2 O
toxicity O
. O

Clinicians B-Claim
should I-Claim
encourage I-Claim
activity I-Claim
for I-Claim
their I-Claim
patients I-Claim
. I-Claim

To O
evaluate O
the O
analgesic O
effect O
, O
safety O
, O
and O
cost-effectiveness O
of O
controlled-release O
oxycodone O
( O
CRO O
) O
to O
control O
postoperative O
pain O
in O
patients O
with O
liver O
cancer O
who O
are O
undergoing O
transarterial O
chemoembolization O
. O

Treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise

The O
PPT O
group O
had O
four O
appointments O
with O
a O
nurse O
who O
assessed O
nine O
symptoms O
on O
a O
0 O
to O
10 O
numeric O
rating O
scale O
( O
NRS O
) O
. O

Women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim

Participants O
were O
randomised O
to O
follow-up O
care O
as O
usual O
( O
3-monthly O
outpatient O
clinic O
visits O
) O
, O
nurse-led O
telephone O
follow-up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O

After B-Premise
RT I-Premise
, I-Premise
QOL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
.003 I-Premise
) I-Premise
proportionally I-Premise
with I-Premise
improved I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
status I-Premise
in I-Premise
group I-Premise
1/group I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
worsened I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
overall I-Premise
QOL I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
maintained I-Premise
or I-Premise
worsened I-Premise
overall I-Premise
QOL I-Premise
. I-Premise

A O
total O
of O
111 O
colorectal O
cancer O
outpatients O
referred O
for O
radiotherapy O
, O
stratified O
by O
staging O
, O
were O
randomly O
assigned O
: O
group O
1 O
( O
G1 O
";" O
n O
= O
37 O
) O
, O
dietary O
counseling O
( O
regular O
foods O
) O
";" O
group O
2 O
( O
G2 O
";" O
n O
= O
37 O
) O
, O
protein O
supplements O
";" O
and O
group O
3 O
( O
G3 O
";" O
n O
= O
37 O
) O
, O
ad O
libitum O
intake O
. O

Histology O
, O
marker O
values O
, O
and O
disease O
extent O
are O
well O
balanced O
in O
the O
treatment O
arms O
of O
the O
two O
comparisons O
. O

All O
patients O
received O
oral O
iron O
supplementation O
. O

At B-Premise
the I-Premise
post-treatment I-Premise
assessment I-Premise
, I-Premise
IMCP I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
b I-Premise
= I-Premise
0.39 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0.76 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

The O
treatment O
cycle O
was O
once O
every O
three O
weeks O
. O

This B-Claim
challenges I-Claim
the I-Claim
current I-Claim
understanding I-Claim
of I-Claim
increasing I-Claim
TMZ I-Claim
dose-intensity I-Claim
by I-Claim
prolonged I-Claim
scheduling I-Claim
. I-Claim

The B-Premise
median I-Premise
AUCs I-Premise
( I-Premise
cycle I-Premise
2-6 I-Premise
) I-Premise
received I-Premise
were I-Premise
6.0 I-Premise
( I-Premise
Arm I-Premise
A I-Premise
) I-Premise
and I-Premise
7.2 I-Premise
( I-Premise
Arm I-Premise
B I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Claim
intervention I-Claim
reduced I-Claim
fatigue I-Claim
and I-Claim
improved I-Claim
vitality I-Claim
, I-Claim
aerobic I-Claim
capacity I-Claim
, I-Claim
muscular I-Claim
strength I-Claim
, I-Claim
and I-Claim
physical I-Claim
and I-Claim
functional I-Claim
activity I-Claim
, I-Claim
and I-Claim
emotional I-Claim
wellbeing I-Claim
, I-Claim
but B-Claim
not I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
RR I-Claim
, I-Claim
PFS I-Claim
, I-Claim
and I-Claim
OS I-Claim
favors I-Claim
PC I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
isotretinoin I-Claim
to I-Claim
an I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
low-dose I-Claim
IFNalpha I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IIA I-Claim
and I-Claim
IIB I-Claim
melanoma I-Claim
had I-Claim
no I-Claim
significant I-Claim
effect I-Claim
on I-Claim
disease-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
and I-Claim
is I-Claim
therefore I-Claim
not I-Claim
recommended I-Claim
. I-Claim

Epoetin O
beta O
rapidly O
increases O
haemoglobin O
( O
Hb O
) O
levels O
and O
improves O
QoL O
in O
anaemic O
patients O
with O
a O
variety O
of O
tumours O
. O

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

Other O
measurements O
included O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
quality-of-life O
scale O
, O
and O
expectation O
of O
acupuncture O
effect O
. O

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open-label I-Premise
exposure I-Premise
. I-Premise

To O
determine O
the O
effect O
of O
a O
nursing-led O
intervention O
on O
quality O
of O
life O
, O
symptom O
intensity O
, O
mood O
, O
and O
resource O
use O
in O
patients O
with O
advanced O
cancer O
. O

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better-tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim

RECIST-defined O
objective O
response O
rate O
( O
ORR O
) O
was O
the O
primary O
end O
point O
. O

251 O
patients O
were O
randomly O
divided O
into O
pemetrexed O
combined O
with O
cisplatin O
group O
( O
PP O
group O
) O
with O
127 O
cases O
and O
gemcitabine O
combined O
with O
cisplatin O
group O
( O
GP O
group O
) O
with O
124 O
cases O
. O

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

The O
objective O
of O
this O
study O
is O
to O
explore O
the O
inflammatory O
modulation O
effect O
of O
glutamine-enriched O
total O
parenteral O
nutrition O
( O
TPN O
) O
by O
investigating O
the O
alterations O
of O
inflammation-related O
cytokines O
in O
gastrointestinal O
( O
GI O
) O
cancer O
patients O
postoperatively O
. O

AT B-Claim
represents I-Claim
a I-Claim
valid I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
MBC I-Claim
. I-Claim

Initial B-Premise
costs I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro8315 I-Premise
vs. I-Premise
euro4820 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Intervention O
group O
patients O
received O
5 O
calls O
from O
a O
specialist O
colorectal O
nurse O
in O
the O
6 O
months O
after O
hospital O
discharge O
. O

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
occurred I-Premise
in I-Premise
69 I-Premise
% I-Premise
( I-Premise
DCF I-Premise
) I-Premise
v I-Premise
59 I-Premise
% I-Premise
( I-Premise
CF I-Premise
) I-Premise
of I-Premise
patients I-Premise
. I-Premise

In B-Premise
the I-Premise
684 I-Premise
patients I-Premise
with I-Premise
data I-Premise
that I-Premise
could I-Premise
be I-Premise
evaluated I-Premise
, I-Premise
ultrasonography I-Premise
of I-Premise
the I-Premise
neck I-Premise
was I-Premise
normal I-Premise
in I-Premise
652 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
stimulated I-Premise
thyroglobulin I-Premise
level I-Premise
was I-Premise
1.0 I-Premise
ng I-Premise
per I-Premise
milliliter I-Premise
or I-Premise
less I-Premise
in I-Premise
621 I-Premise
of I-Premise
the I-Premise
652 I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
without I-Premise
detectable I-Premise
thyroglobulin I-Premise
antibodies I-Premise
. I-Premise

The O
primary O
outcome O
for O
these O
quality-of-life O
analyses O
was O
time O
to O
worsening O
of O
symptoms O
, O
analysed O
for O
all O
randomised O
patients O
. O

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
hot I-Premise
flash I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
with I-Premise
daily I-Premise
hot I-Premise
flashes I-Premise
increasing I-Premise
from I-Premise
baseline I-Premise
by I-Premise
33 I-Premise
% I-Premise
compared I-Premise
with I-Premise
a I-Premise
7 I-Premise
% I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
with I-Premise
exemestane I-Premise
. I-Premise

The B-Premise
event-free I-Premise
period I-Premise
( I-Premise
EFP I-Premise
) I-Premise
, I-Premise
radiologic I-Premise
course I-Premise
of I-Premise
disease I-Premise
, I-Premise
and I-Premise
survival I-Premise
did I-Premise
not I-Premise
improve I-Premise
. I-Premise

Subjects O
were O
randomized O
to O
receive O
either O
an O
individualized O
homeopathic O
single O
remedy O
, O
a O
homeopathic O
combination O
medicine O
, O
or O
placebo O
. O

Records O
of O
nutritional O
assessments O
, O
inflammatory O
status O
, O
and O
postoperative O
complications O
were O
compared O
between O
the O
two O
groups O
. O

In B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
III I-Claim
glioma I-Claim
. I-Claim

Of O
5,187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3,612 O
( O
69.9 O
% O
) O
participated O
in O
the O
QOL O
substudy O
: O
1,799 O
were O
allocated O
to O
placebo O
and O
1,813 O
were O
allocated O
to O
letrozole O
. O

Pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
GCa I-Premise
compared I-Premise
with I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.76 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

Intrapatient B-Claim
dose I-Claim
escalation I-Claim
of I-Claim
carboplatin I-Claim
based I-Claim
on I-Claim
nadir I-Claim
blood I-Claim
counts I-Claim
is I-Claim
feasible I-Claim
and I-Claim
safe I-Claim
. I-Claim

Methadone B-Claim
was I-Claim
significantly I-Claim
less I-Claim
expensive I-Claim
, I-Claim
but I-Claim
required I-Claim
more I-Claim
changes I-Claim
, I-Claim
up I-Claim
and I-Claim
down I-Claim
, I-Claim
of I-Claim
the I-Claim
doses I-Claim
, I-Claim
suggesting I-Claim
that I-Claim
dose I-Claim
titration I-Claim
of I-Claim
this I-Claim
drug I-Claim
requires I-Claim
major I-Claim
clinical I-Claim
expertise I-Claim
. I-Claim

A O
total O
of O
798 O
patients O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stage O
IIB-IV O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
either O
PT O
or O
TC O
at O
3-week O
intervals O
. O

Vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21-day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O

The B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
plus I-Claim
GM-CSF I-Claim
is I-Claim
not I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim

The O
median O
dose O
intensity O
delivered O
for O
C O
and O
E O
reached O
, O
respectively O
, O
85 O
% O
and O
87 O
% O
of O
that O
planned O
in O
the O
CEF O
arm O
and O
96 O
% O
and O
95 O
% O
of O
that O
planned O
in O
the O
EC O
arm O
. O

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

Patients O
with O
GOO O
. O

Using O
KPS O
scores O
, O
changes O
in O
quality O
of O
life O
were O
compared O
before O
and O
after O
the O
treatment O
. O

This B-Premise
negative I-Premise
impact I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
, I-Premise
as I-Premise
for I-Premise
most I-Premise
of I-Premise
the I-Premise
QLQ-C30 I-Premise
scales I-Premise
, I-Premise
the I-Premise
QOL I-Premise
scores I-Premise
of I-Premise
HDC I-Premise
patients I-Premise
tend I-Premise
to I-Premise
improve I-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
than I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
standard I-Premise
chemotherapy I-Premise
. I-Premise

During O
the O
first O
year O
of O
treatment O
, O
HRQOL O
and O
symptoms O
of O
depression O
were O
analyzed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
and O
its O
Endocrine O
Symptom O
Subscale O
( O
ES O
) O
, O
and O
the O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
( O
CES-D O
) O
, O
respectively O
. O

Significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
IMCP I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
-6.56 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
symptom-related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
-0.47 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise

Mood O
was O
measured O
by O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
range O
, O
0-60 O
) O
. O

At O
baseline O
, O
domain O
scores O
were O
similar O
between O
arms O
. O

Complete B-Claim
fibroid I-Claim
infarction I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
total I-Claim
freedom I-Claim
from I-Claim
a I-Claim
subsequent I-Claim
reintervention I-Claim
. I-Claim

A B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
CCSP I-Premise
on I-Premise
QOL I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
showed I-Premise
that I-Premise
the I-Premise
CCSP I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
psychological/spiritual I-Premise
well-being I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

Three B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
: I-Premise
2 I-Premise
patients I-Premise
in I-Premise
the I-Premise
surgical I-Premise
arms I-Premise
( I-Premise
one I-Premise
late I-Premise
pulmonary I-Premise
toxicity I-Premise
and I-Premise
one I-Premise
pulmonary I-Premise
embolus I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
radiation I-Premise
arm I-Premise
( I-Premise
radiation I-Premise
pneumonitis I-Premise
) I-Premise
. I-Premise

This O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand-assisted O
laparoscopic O
( O
LRP O
) O
versus O
open O
restorative O
proctocolectomy O
( O
ORP O
) O
. O

The B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise

Patients B-Premise
who I-Premise
preferred I-Premise
RET I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
RET I-Premise
compared I-Premise
with I-Premise
UC I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4.3-28.7 I-Premise
";" I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
or I-Premise
AET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.1-23.4 I-Premise
";" I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

Scores B-Premise
on I-Premise
a I-Premise
scale I-Premise
assessing I-Premise
daily I-Premise
functioning I-Premise
and I-Premise
enjoyment I-Premise
( I-Premise
Q-LES-Q I-Premise
) I-Premise
improved I-Premise
from I-Premise
year I-Premise
7 I-Premise
to I-Premise
year I-Premise
9 I-Premise
. I-Premise

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O

Comparison B-Premise
of I-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=815 I-Premise
) I-Premise
versus I-Premise
oestrogen I-Premise
therapy I-Premise
( I-Premise
n=826 I-Premise
) I-Premise
outcomes I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

Survival B-Premise
without I-Premise
performance-status I-Premise
deterioration I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain-free I-Premise
survival I-Premise
( I-Premise
p=0.003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise

If O
replicated O
, O
these O
results O
may O
inform O
clinical O
practice O
. O

Fatigue O
is O
a O
frequent O
problem O
after O
surgical O
treatment O
of O
solid O
tumours O
. O

Dizziness B-Premise
( I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1.2 I-Premise
% I-Premise
vs. I-Premise
5.2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

treosulfan O
for O
the O
treatment O
of O
relapsed O
ovarian O
carcinoma O
, O
women O
aged O
65 O
years O
or O
older O
were O
included O
in O
this O
prospective O
multicenter O
study O
. O

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
OS I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
IHC-positive I-Premise
subgroup I-Premise
( I-Premise
p=0.0233 I-Premise
) I-Premise
. I-Premise

Response O
rate O
( O
RR O
) O
was O
evaluated O
after O
every O
four O
courses O
. O

End O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
and O
response O
duration O
( O
RD O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
overall O
survival O
( O
OS O
) O
. O

Nutritional O
intake O
( O
diet O
history O
) O
, O
status O
( O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QoL O
( O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
, O
and O
3 O
months O
after O
radiotherapy O
. O

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
QOL I-Premise
. I-Premise

Subjects O
( O
N O
= O
27 O
) O
were O
patients O
admitted O
for O
some O
type O
of O
surgical O
procedure O
of O
the O
brain O
. O

Patients O
were O
assessed O
for O
response O
, O
toxicity O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
the O
effect O
of O
treatment O
on O
Bcl-2 O
levels O
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
. O

Patients O
initially O
randomly O
assigned O
to O
the O
sham O
group O
were O
crossed O
over O
to O
TRUE O
acupuncture O
starting O
at O
week O
7 O
. O

The O
CCSP O
components O
included O
educational O
information O
, O
cognitive O
restructuring O
, O
coping O
skills O
enhancement O
, O
and O
relaxation O
with O
guided O
imagery O
. O

Patients O
, O
and O
investigators O
undertaking O
interventions O
, O
assessing O
outcomes O
, O
and O
analysing O
data O
, O
were O
not O
masked O
to O
group O
assignment O
. O

In O
nonrandomized O
trials O
, O
doses O
studied O
have O
ranged O
from O
135 O
mg/m2 O
to O
250 O
mg/m2 O
administered O
over O
24 O
hours O
with O
premedication O
to O
avoid O
hypersensitivity O
reactions O
( O
HSRs O
) O
. O

For B-Claim
malignant I-Claim
pleural I-Claim
mesothelioma I-Claim
( I-Claim
MPM I-Claim
) I-Claim
patients I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
maintaining I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQOL I-Claim
) I-Claim
is I-Claim
important I-Claim
. I-Claim

This O
study O
tested O
the O
efficacy O
of O
a O
caregiver-assisted O
CST O
protocol O
in O
a O
sample O
of O
patients O
with O
lung O
cancer O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
scores I-Premise
at I-Premise
months I-Premise
9 I-Premise
and I-Premise
12 I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
and I-Premise
P I-Premise
= I-Premise
.93 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The O
8-week O
programme O
of O
2 O
h O
sessions O
comprised O
of O
thematic O
discussions O
, O
information O
and O
training O
in O
stress O
management O
techniques O
. O

Depression O
is O
common O
among O
older O
cancer O
patients O
, O
but O
little O
is O
known O
about O
the O
optimal O
approach O
to O
caring O
for O
this O
population O
. O

Biopsies O
( O
n=168 O
) O
were O
taken O
without O
complications O
. O

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
( I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
: I-Premise
median I-Premise
5 I-Premise
vs I-Premise
8 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
with I-Premise
more I-Premise
patients I-Premise
living I-Premise
more I-Premise
days I-Premise
with I-Premise
a I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
of I-Premise
2 I-Premise
or I-Premise
more I-Premise
than I-Premise
after I-Premise
stent I-Premise
placement I-Premise
( I-Premise
72 I-Premise
vs I-Premise
50 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Primary O
end-point O
was O
overall O
response O
to O
first-line O
treatment O
among O
TS O
high O
patients O
. O

Among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
P=.05 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

Patients O
received O
a O
median O
of O
six O
cycles O
in O
both O
arms O
. O

The O
initial O
treatment O
consisted O
of O
taking O
1 O
capsule O
daily O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
for O
the O
first O
week O
and O
2 O
capsules O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
daily O
for O
4 O
additional O
weeks O
. O

The B-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
no I-Premise
change I-Premise
in I-Premise
OPS-DNA I-Premise
concentration I-Premise
, I-Premise
although O
the B-Premise
placebo I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
DNA I-Premise
concentration I-Premise
during I-Premise
the I-Premise
drug I-Premise
trial I-Premise
( I-Premise
P=.045 I-Premise
) I-Premise
. I-Premise

Administration O
of O
ESAs O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on-time O
chemotherapy O
delivery O
. O

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
66.7 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
and I-Premise
64.4 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
AT I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.82 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
fludarabine I-Premise
had I-Premise
higher I-Premise
scores I-Premise
for I-Premise
social I-Premise
function I-Premise
( I-Premise
P I-Premise
=.008 I-Premise
) I-Premise
";" I-Premise
no B-Premise
other I-Premise
differences I-Premise
in I-Premise
QoL I-Premise
were I-Premise
detected I-Premise
. I-Premise

Thyroid B-Premise
ablation I-Premise
was I-Premise
complete I-Premise
in I-Premise
631 I-Premise
of I-Premise
the I-Premise
684 I-Premise
patients I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage-type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

CD-DP O
was O
given O
intravenously O
at O
a O
dose O
of O
3 O
mg/m O
( O
2 O
) O
on O
days O
1-5 O
and O
days O
8-12 O
, O
and O
then O
at O
a O
dose O
of O
7 O
mg/m O
( O
2 O
) O
twice O
a O
week O
. O

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
of I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
or=2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise

For O
patients O
undergoing O
oncologic O
surgery O
, O
the O
quality O
of O
life O
( O
QoL O
) O
is O
generally O
accepted O
as O
an O
important O
outcome O
parameter O
in O
addition O
to O
long-term O
survival O
, O
mortality O
and O
complication O
rates O
. O

Women O
with O
a O
history O
of O
breast O
cancer O
who O
had O
completed O
all O
surgery O
, O
chemotherapy O
, O
and O
radiation O
treatment O
and O
who O
had O
an O
average O
of O
at O
least O
three O
hot O
flashes O
per O
day O
for O
the O
previous O
month O
. O

Hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim

Analysis O
was O
by O
intention O
to O
treat O
. O

Forty-five O
patients O
were O
eligible O
, O
of O
whom O
34 O
were O
randomized O
( O
mean O
( O
s.d O
. O
) O
age O
70 O
( O
11Â·8 O
) O
years O
) O
. O

QOL O
was O
assessed O
by O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
the O
lung O
cancer O
module O
QLQ-LC13 O
. O

The O
2-year O
risk O
of O
progression O
was O
calculated O
for O
baseline O
PSA O
, O
'fast O
' O
and O
'slow O
' O
PSA O
decline O
to O
< O
4 O
ng/ml O
( O
60 O
days O
cut-off O
) O
, O
PSA O
nadir O
, O
performance O
status O
and O
pain O
. O

Additional O
analyses O
included O
the O
Short O
Form-6 O
Dimensions O
( O
SF-6D O
) O
quality-of-life O
scale O
and O
a O
general O
impression O
( O
GI O
) O
of O
patient O
satisfaction O
with O
treatment O
at O
the O
end O
of O
the O
phase O
. O

Patients O
with O
proven O
metastatic O
colorectal O
cancer O
, O
which O
had O
progressed O
within O
6 O
months O
of O
treatment O
with O
fluorouracil O
, O
were O
randomly O
assigned O
either O
300-350 O
mg/m2 O
irinotecan O
every O
3 O
weeks O
with O
supportive O
care O
or O
supportive O
care O
alone O
, O
in O
a O
2:1 O
ratio O
. O

Median O
ECOG O
was O
1 O
, O
and O
median O
number O
of O
prior O
chemotherapy O
regimens O
was O
2 O
. O

A O
prospective O
randomized O
study O
was O
conducted O
from O
January O
2003 O
. O

Incidence B-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
consistent I-Premise
with I-Premise
previously I-Premise
reported I-Premise
rates I-Premise
. I-Premise

Prespecified O
analyses O
examined O
rates O
of O
amenorrhea O
by O
treatment O
arm O
, O
the O
relationship O
between O
amenorrhea O
and O
QOL O
, O
and O
QOL O
by O
treatment O
arm O
. O

Addition B-Claim
of I-Claim
temozolomide I-Claim
during I-Claim
and I-Claim
after I-Claim
radiotherapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
glioblastoma I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
without I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQOL I-Claim
. I-Claim

Dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim

One O
thousand O
eighty-eight O
women O
were O
randomly O
allocated O
to O
sentinel-lymph-node O
biopsy O
followed O
by O
axillary O
clearance O
if O
the O
sentinel O
node O
was O
positive O
or O
not O
detected O
( O
SNBM O
) O
or O
routine O
axillary O
clearance O
( O
RAC O
, O
sentinel-lymph-node O
biopsy O
followed O
immediately O
by O
axillary O
clearance O
) O
. O

Time B-Premise
to I-Premise
final I-Premise
healing I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
on I-Premise
the I-Premise
CWIS I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
RELP I-Premise
than I-Premise
in I-Premise
those I-Premise
receiving I-Premise
UM I-Premise
. I-Premise

Baseline O
questionnaires O
were O
available O
for O
490 O
( O
86 O
% O
) O
patients O
. O

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Before O
the O
knowledge O
that O
5 O
years O
of O
adjuvant O
tamoxifen O
is O
less O
efficacious O
than O
2 O
to O
3 O
years O
of O
tamoxifen O
followed O
by O
2 O
to O
3 O
years O
of O
anastrozole/exemestane O
, O
we O
designed O
a O
multicenter O
double-blind O
randomized O
controlled O
trial O
in O
women O
taking O
tamoxifen O
with O
a O
thickened O
endometrium O
to O
compare O
uterine O
and O
quality-of-life O
parameters O
between O
those O
switching O
to O
anastrozole O
and O
those O
continuing O
tamoxifen O
. O

Transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O

Grade O
3 O
or O
4 O
palmar-plantar O
erythrodysesthesia O
was O
documented O
in O
a O
higher O
proportion O
of O
PLD O
patients O
( O
6 O
% O
) O
versus O
GEM O
patients O
( O
0 O
% O
";" O
P O
= O
.061 O
) O
. O

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

EORTC O
QLQ-C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end-of-treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

This B-Premise
trend I-Premise
for I-Premise
OS I-Premise
benefit I-Premise
for I-Premise
GEM-CAP I-Premise
was I-Premise
consistent I-Premise
across I-Premise
different I-Premise
prognostic I-Premise
subgroups I-Premise
according I-Premise
to I-Premise
baseline I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
stage I-Premise
and I-Premise
performance I-Premise
status I-Premise
) I-Premise
and I-Premise
remained I-Premise
after I-Premise
adjusting I-Premise
for I-Premise
these I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
P I-Premise
= I-Premise
.077 I-Premise
) I-Premise
. I-Premise

Final O
planned O
overall O
survival O
( O
OS O
) O
analysis O
from O
EGF104900 O
is O
reported O
here O
. O

Efficacy B-Claim
is I-Claim
low I-Claim
but I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
other I-Claim
treatments I-Claim
used I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

This O
analysis O
investigated O
the O
treatment O
effects O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
. O

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.52-0.75 I-Premise
";" I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
any I-Premise
outcome I-Premise
between I-Premise
groups I-Premise
. I-Premise

Treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1.54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
to I-Premise
2.00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.19 I-Premise
to I-Premise
2.15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise

Thus O
, O
an O
alternative O
regimen O
without O
significant O
neurotoxicity O
was O
evaluated O
by O
comparing O
gemcitabine O
plus O
carboplatin O
with O
single-agent O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
. O

The B-Premise
combined I-Premise
treatment I-Premise
group I-Premise
demonstrated I-Premise
13 I-Premise
cases I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
22 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
. I-Premise

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

To O
compare O
the O
efficacy O
of O
low-frequency O
low-intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

Numerous O
studies O
have O
examined O
the O
comorbidity O
of O
depression O
with O
cancer O
, O
and O
some O
have O
indicated O
that O
depression O
may O
be O
associated O
with O
cancer O
progression O
or O
survival O
. O

Assessments O
included O
weight O
, O
symptoms O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
, O
and O
quality O
of O
life O
by O
the O
Functional O
Assessment O
of O
Anorexia/Cachexia O
Therapy O
( O
FAACT O
) O
questionnaire O
. O

The O
patients O
were O
observed O
for O
a O
minimum O
of O
3 O
years O
. O

Of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
Karnofsky O
performance O
score O
of O
90-100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
N2 O
disease O
. O

This B-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
a I-Claim
brief I-Claim
, I-Claim
predominantly I-Claim
group-based I-Claim
resilience I-Claim
training I-Claim
intervention I-Claim
is I-Claim
feasible I-Claim
in I-Claim
patients I-Claim
with I-Claim
previous I-Claim
breast I-Claim
cancer I-Claim
";" I-Claim
also I-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
efficacious I-Claim
. I-Claim

The O
purpose O
of O
this O
2-group O
randomized O
controlled O
pilot O
feasibility O
study O
was O
to O
test O
short-term O
effects O
of O
a O
12-week O
Mindful O
Movement O
Program O
( O
MMP O
) O
intervention O
combining O
mindfulness O
with O
self-directed O
movement O
on O
QOL O
and O
mindfulness O
in O
female O
BCSs O
50 O
years O
or O
older O
and O
at O
12 O
months O
or O
more O
following O
treatment O
. O

Differences B-Premise
were I-Premise
most I-Premise
apparent I-Premise
shortly I-Premise
after I-Premise
the I-Premise
time I-Premise
of I-Premise
completion I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise

Epoetin B-Claim
beta I-Claim
30,000 I-Claim
IU I-Claim
once I-Claim
weekly I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
treatment I-Claim
of I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

The B-Premise
RR I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.3492 I-Premise
) I-Premise
. I-Premise

From O
February O
2006 O
to O
March O
2007 O
, O
291 O
patients O
were O
enrolled O
and O
randomized O
, O
after O
total O
thyroidectomy O
: O
( O
1 O
) O
withdrawal O
of O
levothyroxine O
( O
LT4 O
) O
for O
4 O
weeks O
( O
T4-WD O
Group O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
withdrawal O
of O
LT4 O
for O
4 O
weeks O
plus O
2 O
weeks O
on O
and O
then O
2 O
weeks O
off O
liothyronine O
( O
LT3 O
) O
( O
T3-WD O
Group O
, O
n O
= O
133 O
) O
, O
and O
( O
3 O
) O
rhTSH O
administration O
( O
rhTSH O
Group O
, O
n O
= O
69 O
) O
. O

This O
study O
is O
registered O
, O
ISRCTN87786644 O
. O

This B-Claim
study I-Claim
demonstrates I-Claim
the I-Claim
feasibility I-Claim
and I-Claim
effectiveness I-Claim
of I-Claim
a I-Claim
psycho-educational I-Claim
intervention I-Claim
, I-Claim
which I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
reduction I-Claim
of I-Claim
those I-Claim
negative I-Claim
affects I-Claim
which I-Claim
are I-Claim
present I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
treatment I-Claim
. I-Claim

Pain O
training O
and O
control O
interventions O
were O
matched O
for O
materials O
and O
method O
. O

The B-Premise
mean I-Premise
BAP I-Premise
increased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
but I-Premise
decreased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
C I-Premise
patients I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
15 I-Premise
months I-Premise
. I-Premise

major O
cardiovascular O
disease O
, O
osteoporotic O
fractures O
, O
and O
breast O
cancer O
. O

Patients O
with O
multiple O
myeloma O
who O
were O
starting O
antimyeloma O
treatment O
were O
randomly O
assigned O
in O
a O
1:1 O
ratio O
to O
receive O
one O
of O
two O
doses O
of O
pamidronate O
( O
30 O
mg O
or O
90 O
mg O
) O
given O
by O
intravenous O
infusion O
once O
a O
month O
for O
at O
least O
3 O
years O
. O

Data O
were O
collected O
prior O
to O
intervention O
and O
post-intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O

To O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well-being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1,169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
( I-Premise
TOI I-Premise
) I-Premise
scores I-Premise
( I-Premise
physical I-Premise
well-being I-Premise
, I-Premise
functional I-Premise
well-being I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
concerns I-Premise
subscales I-Premise
in I-Premise
FACT-B+4 I-Premise
) I-Premise
and I-Premise
recovered I-Premise
more I-Premise
slowly I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
SNB I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

To O
observe O
the O
effect O
of O
TCM O
therapy O
for O
removing O
toxic O
substance O
and O
unblocking O
meridians O
on O
post-radiation O
quality O
of O
life O
( O
QOF O
) O
in O
55 O
patients O
with O
lung O
cancer O
. O

Age-adjusted B-Claim
risk I-Claim
profiles I-Claim
that I-Claim
consider I-Claim
patient-reported I-Claim
outcomes I-Claim
enable I-Claim
patients I-Claim
to I-Claim
adapt I-Claim
to I-Claim
their I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
, I-Claim
such I-Claim
as I-Claim
considering I-Claim
the I-Claim
trade-offs I-Claim
between I-Claim
delayed I-Claim
endocrine I-Claim
symptoms I-Claim
, I-Claim
but I-Claim
higher I-Claim
risk I-Claim
of I-Claim
permanent I-Claim
menopause I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
and I-Claim
immediate I-Claim
but I-Claim
reversible I-Claim
endocrine I-Claim
symptoms I-Claim
with I-Claim
goserelin I-Claim
, I-Claim
in I-Claim
younger I-Claim
premenopausal I-Claim
patients I-Claim
. I-Claim

With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient-related O
factors O
. O

We O
randomly O
assigned O
56 O
patients O
to O
the O
open O
oesophagectomy O
group O
and O
59 O
to O
the O
minimally O
invasive O
oesophagectomy O
group O
. O

At B-Premise
1 I-Premise
year I-Premise
, I-Premise
symptom I-Premise
scores I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
. I-Premise

After O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
A O
) O
or O
rehabilitation O
alone O
( O
group O
B O
) O
, O
for O
16 O
wk O
. O

These B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4.5-month I-Claim
median I-Claim
OS I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
HER2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
HER2-positive I-Claim
MBC I-Claim
. I-Claim

The B-Premise
functional I-Premise
well-being I-Premise
component I-Premise
of I-Premise
the I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
";" I-Premise
N I-Premise
predicted I-Premise
most I-Premise
significantly I-Premise
for I-Premise
LRC I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0004 I-Premise
) I-Premise
. I-Premise

We O
compared O
initial O
costs O
and O
costs O
during O
follow-up O
. O

After B-Premise
intervention I-Premise
, I-Premise
EG I-Premise
participants I-Premise
showed I-Premise
improved I-Premise
QOL I-Premise
via I-Premise
decreased I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
increased I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatments I-Premise
in I-Premise
hematological I-Premise
and I-Premise
nonhematological I-Premise
toxic I-Premise
effects I-Premise
, I-Premise
except B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
rash I-Premise
, I-Premise
constipation I-Premise
, I-Premise
or I-Premise
neuropathy I-Premise
. I-Premise

Health O
and O
cost O
outcomes O
in O
the O
two O
arms O
were O
compared O
, O
and O
cost-effectiveness O
was O
estimated O
. O

With B-Premise
94 I-Premise
patients I-Premise
still I-Premise
alive I-Premise
, I-Premise
the I-Premise
one-year I-Premise
probability I-Premise
of I-Premise
survival I-Premise
was I-Premise
61 I-Premise
% I-Premise
, I-Premise
54 I-Premise
% I-Premise
, I-Premise
and I-Premise
59 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Prospective O
randomized O
study O
that O
included O
60 O
patients O
( O
45 O
women O
, O
15 O
men O
";" O
mean O
age O
, O
55.2 O
years O
) O
with O
recurrent O
malignant O
pleural O
effusion O
between O
January O
2005 O
and O
January O
2008 O
. O

Paclitaxel O
was O
administered O
as O
a O
3-hour O
intravenous O
infusion O
every O
3 O
weeks O
. O

The B-Claim
safer I-Claim
and I-Claim
simpler I-Claim
RY I-Claim
method I-Claim
may I-Claim
be I-Claim
a I-Claim
more I-Claim
suitable I-Claim
reconstruction I-Claim
method I-Claim
than I-Claim
INT I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
. I-Claim

Between-group B-Premise
differences I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
were I-Premise
not I-Premise
significant I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
and B-Premise
no I-Premise
significant I-Premise
effects I-Premise
emerged I-Premise
on I-Premise
the I-Premise
secondary I-Premise
end I-Premise
points I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
severe I-Premise
ARSR I-Premise
between I-Premise
the I-Premise
groups I-Premise
at I-Premise
any I-Premise
point I-Premise
of I-Premise
assessment I-Premise
. I-Premise

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

Shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

We O
compared O
efficacy O
of O
gefitinib O
with O
gemcitabine O
and O
cisplatin O
( O
GP O
) O
chemotherapy O
in O
this O
group O
of O
patients O
as O
first-line O
therapy O
. O

A B-Premise
significantly I-Premise
lower I-Premise
serum I-Premise
interleukin-6 I-Premise
level I-Premise
was I-Premise
found I-Premise
in I-Premise
comparing I-Premise
glutamine-enriched I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
in I-Premise
interleukin-10 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.374 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-Î± I-Premise
levels I-Premise
( I-Premise
P I-Premise
= I-Premise
0.653 I-Premise
) I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrates I-Claim
comparable I-Claim
remnant I-Claim
ablation I-Claim
rates I-Claim
in I-Claim
patients I-Claim
prepared I-Claim
for I-Claim
131I I-Claim
remnant I-Claim
ablation I-Claim
with I-Claim
3.7 I-Claim
GBq I-Claim
by I-Claim
either I-Claim
administering I-Claim
rhTSH I-Claim
or I-Claim
withholding I-Claim
thyroid I-Claim
hormone I-Claim
. I-Claim

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
QLQ-LC13 O
, O
and O
overall O
survival O
. O

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
. I-Premise

Participants O
drank O
4 O
oz O
. O

Bone O
resorption O
markers O
measured O
included O
urinary O
calcium O
( O
uCa O
) O
, O
hydroxyproline O
( O
Hyp O
) O
, O
and O
the O
collagen O
breakdown O
products O
: O
NTx O
, O
Crosslaps O
and O
Free O
Dpd O
. O

Compared O
with O
placebo O
, O
prophylactic O
treatment O
with O
bisphosphonates O
reduces O
risk O
of O
skeletal O
events O
in O
patients O
with O
multiple O
myeloma O
. O

Spiritual O
well-being O
and O
sense O
of O
meaning O
are O
important O
concerns O
for O
clinicians O
who O
care O
for O
patients O
with O
cancer O
. O

This O
study O
is O
registered O
as O
ISRCTN83176944 O
. O

A O
total O
of O
724 O
patients O
( O
51 O
% O
with O
limited O
and O
49 O
% O
with O
extensive O
disease O
) O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
thalidomide O
capsules O
, O
100-200 O
mg O
daily O
for O
up O
to O
2 O
years O
. O

Patients O
' O
quality O
of O
life O
was O
evaluated O
with O
the O
Cardiff O
Wound O
Impact O
Schedule O
( O
CWIS O
) O
. O

N O
, O
N-diethyl-2- O
[ O
-4 O
( O
phenylmethyl O
) O
phenoxy O
] O
ethanamine O
( O
DPPE O
";" O
tesmilifene O
) O
is O
a O
novel O
agent O
that O
augments O
chemotherapy O
cytotoxicity O
in O
vitro O
and O
in O
vivo O
. O

Patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3-year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

These B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise

Three O
National O
Health O
Service O
oncology O
clinics O
in O
Scotland O
and O
community O
exercise O
facilities O
. O

Breast O
cancer O
outcomes O
included O
recurrence O
as O
well O
as O
disease-free O
and O
overall O
survival O
. O

Factors O
from O
the O
EORTC O
QLQ-C30 O
were O
all O
function O
scales O
, O
fatigue O
, O
nausea/vomiting O
, O
pain O
, O
dyspnoea O
, O
insomnia O
, O
loss O
of O
appetite O
and O
global O
QL O
. O

Forty-one O
participants O
were O
enrolled O
and O
36 O
completed O
the O
trial O
. O

Many O
patients O
with O
cancer O
experience O
depression O
and O
anxiety O
, O
and O
an O
associated O
decrease O
in O
quality O
of O
life O
( O
QOL O
) O
during O
radiation O
therapy O
( O
RT O
) O
. O

It O
is O
, O
however O
, O
unclear O
whether O
the O
size O
and O
location O
of O
incisions O
affect O
body O
image O
and O
QOL O
. O

An O
intention-to-treat O
analysis O
was O
carried O
out O
. O

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800-mg/d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low- I-Premise
and I-Premise
high-dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160-mg/d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17.3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17.9 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

During B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
there I-Premise
were I-Premise
13 I-Premise
major I-Premise
adverse I-Premise
events I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
and I-Premise
10 I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
( I-Premise
P=0.22 I-Premise
) I-Premise
, I-Premise
mostly I-Premise
related I-Premise
to I-Premise
the I-Premise
intervention I-Premise
. I-Premise

The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula O
Weleda O
cream O
vs. O
Essex O
cream O
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O

In O
addition O
to O
known O
clinical O
factors O
, O
patient-assessed B-Claim
QL I-Claim
variables I-Claim
appear I-Claim
to I-Claim
be I-Claim
prognostic I-Claim
for I-Claim
survival I-Claim
and I-Claim
response I-Claim
to I-Claim
chemotherapy I-Claim
in I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
HDCT I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim

As B-Premise
of I-Premise
October I-Premise
15 I-Premise
, I-Premise
2005 I-Premise
, I-Premise
eight I-Premise
of I-Premise
26 I-Premise
patients I-Premise
in I-Premise
the I-Premise
CONT I-Premise
group I-Premise
and I-Premise
26 I-Premise
of I-Premise
32 I-Premise
patients I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
had I-Premise
documented I-Premise
disease I-Premise
progression I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

There O
are O
no O
known O
effective O
treatments O
for O
painful O
chemotherapy-induced O
peripheral O
neuropathy O
. O

An B-Premise
objective I-Premise
response I-Premise
was I-Premise
observed I-Premise
in I-Premise
28 I-Premise
, I-Premise
21 I-Premise
, I-Premise
22 I-Premise
and I-Premise
10 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

From O
September O
1999 O
to O
April O
2002 O
, O
356 O
patients O
( O
178 O
participants O
received O
gemcitabine-carboplatin O
, O
178 O
received O
carboplatin O
only O
) O
were O
randomized O
to O
treatment O
. O

Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ-C30/LC-13 O
) O
were O
also O
collected O
. O

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT-B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

Breast O
cancer O
patients O
who O
were O
initiating O
adjuvant O
chemotherapy O
( O
N=242 O
) O
were O
assigned O
randomly O
to O
receive O
usual O
care O
( O
UC O
) O
( O
n=82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
) O
( O
n=82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
) O
( O
n=78 O
) O
for O
the O
duration O
of O
chemotherapy O
. O

Results O
Baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O

There O
were O
no O
statistically O
significant O
differences O
in O
the O
distribution O
of O
variables O
used O
to O
assess O
randomization O
success O
between O
the O
HBO O
and O
standard O
treatment O
groups O
. O

We O
assessed O
HRQOL O
at O
baseline O
and O
at O
every O
3 O
months O
during O
treatment O
until O
progression O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
quality O
of O
life O
questionnaire O
core-30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
brain O
cancer O
module O
( O
EORTC O
BN-20 O
) O
. O

Patients O
were O
stratified O
by O
menopausal O
and O
hormone-receptor O
status O
. O

There B-Premise
were I-Premise
no I-Premise
unexpected I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Even O
though O
both B-Premise
treatment I-Premise
modalities I-Premise
resulted I-Premise
in I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
arm I-Premise
volume I-Premise
( I-Premise
12.2 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
II I-Premise
and I-Premise
14.9 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
I I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
no B-Premise
significant I-Premise
difference I-Premise
( I-Premise
p=0.582 I-Premise
) I-Premise
was I-Premise
found I-Premise
between I-Premise
those I-Premise
two I-Premise
groups I-Premise
. I-Premise

Men O
in O
SPCG-4 O
had O
a O
median O
follow-up O
of O
12Â·2 O
years O
( O
range O
7-17 O
) O
and O
a O
median O
age O
of O
77Â·0 O
years O
( O
range O
61-88 O
) O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

This O
trial O
is O
registered O
with O
the O
Netherlands O
Trial O
Register O
, O
NTR O
TC O
2452 O
. O

Misoprostol O
is O
a O
synthetic O
prostaglandin O
E1 O
analogue O
, O
with O
properties O
of O
a O
mucosal O
cytoprotectant O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
40,000 O
U O
subcutaneously O
once O
weekly O
or O
placebo O
at O
the O
beginning O
of O
4 O
cycles O
of O
chemotherapy O
administered O
over O
12 O
weeks O
. O

Over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost-effective I-Premise
treatment I-Premise
. I-Premise

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

Survival O
curves O
were O
calculated O
by O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
Cox O
proportional O
hazards O
model O
. O

Superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38.9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7.6 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise

After O
removing O
patients O
who O
did O
not O
complete O
the O
follow-up O
survey O
or O
censured O
cases O
, O
24 O
patients O
in O
the O
RY O
group O
and O
18 O
patients O
in O
the O
INT O
group O
were O
clinically O
available O
and O
their O
postoperative O
status O
was O
assessed O
. O

GE O
does O
not O
warrant O
further O
investigation O
in O
unselected O
pancreatic O
cancer O
patients O
. O

Grade B-Premise
3-4 I-Premise
toxicities I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
cytokine-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
medroxyprogesterone-treated I-Premise
patients I-Premise
. I-Premise

SGN-15 O
is O
an O
antibody-drug O
conjugate O
( O
ADC O
) O
, O
consisting O
of O
a O
chimeric O
murine O
monoclonal O
antibody O
recognizing O
the O
Lewis O
Y O
( O
Le O
( O
y O
) O
) O
antigen O
, O
conjugated O
to O
doxorubicin O
. O

The O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O

This O
includes O
cross-sectional O
comparisons O
, O
together O
with O
a O
global O
test O
for O
the O
QOL O
response O
rate O
. O

The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT-I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O

Everolimus O
( O
EVE O
) O
+exemestane O
( O
EXE O
";" O
n O
= O
485 O
) O
more O
than O
doubled O
median O
progression-free O
survival O
versus O
placebo O
( O
PBO O
) O
+ O
EXE O
( O
n O
= O
239 O
) O
, O
with O
a O
manageable O
safety O
profile O
and O
no O
deterioration O
in O
health-related O
quality-of-life O
( O
HRQOL O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
advanced O
breast O
cancer O
( O
ABC O
) O
who O
recurred O
or O
progressed O
on/after O
nonsteroidal O
aromatase O
inhibitor O
( O
NSAI O
) O
therapy O
. O

Randomized B-Claim
trials I-Claim
in I-Claim
fluorouracil I-Claim
( I-Claim
FU I-Claim
) I-Claim
-refractory I-Claim
colorectal I-Claim
cancer I-Claim
demonstrate I-Claim
significant I-Claim
survival I-Claim
advantages I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
irinotecan I-Claim
. I-Claim

Mean B-Premise
use I-Premise
of I-Premise
additional I-Premise
analgesia I-Premise
( I-Premise
intravenous I-Premise
morphine I-Premise
equivalents I-Premise
) I-Premise
was I-Premise
12 I-Premise
mg I-Premise
in I-Premise
the I-Premise
WIC I-Premise
arm I-Premise
and I-Premise
9 I-Premise
mg I-Premise
in I-Premise
the I-Premise
epidural I-Premise
arm I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
end I-Premise
of I-Premise
RT I-Premise
, I-Premise
global I-Premise
HRQOL I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
low I-Premise
compliance I-Premise
does I-Premise
not I-Premise
allow I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

Follow-up O
assessment O
for O
our O
primary O
end O
point O
was O
96 O
% O
( O
117 O
of O
122 O
) O
at O
postintervention O
and O
90 O
% O
( O
110 O
of O
122 O
) O
at O
6-month O
follow-up O
. O

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

It B-Claim
is I-Claim
not I-Claim
known I-Claim
whether I-Claim
imatinib I-Claim
may I-Claim
be I-Claim
stopped I-Claim
in I-Claim
patients I-Claim
in I-Claim
whom I-Claim
disease I-Claim
is I-Claim
controlled I-Claim
. I-Claim

Patients B-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
gave I-Premise
lower I-Premise
ratings I-Premise
for I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
dysfunctions I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
disabilities I-Premise
( I-Premise
P I-Premise
= I-Premise
0.5 I-Premise
) I-Premise
. I-Premise

Incorporation B-Claim
of I-Claim
docetaxel I-Claim
, I-Claim
as I-Claim
in I-Claim
DCF I-Claim
or I-Claim
with I-Claim
other I-Claim
active I-Claim
drug I-Claim
( I-Claim
s I-Claim
) I-Claim
, I-Claim
is I-Claim
a I-Claim
new I-Claim
therapy I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
untreated I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

Maintenance O
therapy O
can O
delay O
progression O
and O
prolong O
survival O
in O
metastatic O
non-small-cell O
lung O
cancer O
( O
mNSCLC O
) O
. O

No B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise

In B-Claim
contrast I-Claim
, I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
ER-positive I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
endocrine-responsive I-Claim
) I-Claim
, I-Claim
they I-Claim
obtained I-Claim
no I-Claim
benefit I-Claim
from I-Claim
the I-Claim
combination I-Claim
treatment I-Claim
compared I-Claim
with I-Claim
tamoxifen I-Claim
alone I-Claim
. I-Claim

Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

More B-Premise
patients I-Premise
survived I-Premise
> I-Premise
/= I-Premise
3 I-Premise
years I-Premise
in I-Premise
the I-Premise
D3P I-Premise
and I-Premise
D1P I-Premise
arms I-Premise
( I-Premise
18.6 I-Premise
% I-Premise
and I-Premise
16.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
MP I-Premise
arm I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Participants O
were O
assessed O
before O
cancer O
treatment O
( O
T1 O
) O
, O
postintervention O
( O
T2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1-year O
follow-up O
( O
T3 O
) O
. O

However B-Claim
, I-Claim
its I-Claim
safety I-Claim
should I-Claim
be I-Claim
confirmed I-Claim
by I-Claim
the I-Claim
results I-Claim
of I-Claim
larger I-Claim
randomized I-Claim
trials I-Claim
and I-Claim
meta-analyses I-Claim
. I-Claim

Measurable B-Claim
improvement I-Claim
in I-Claim
a I-Claim
general I-Claim
QOL I-Claim
measure I-Claim
was I-Claim
not I-Claim
demonstrated I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
patients I-Claim
' I-Claim
appetite I-Claim
or I-Claim
QOL I-Claim
were I-Claim
found I-Claim
either I-Claim
between I-Claim
CE I-Claim
, I-Claim
THC I-Claim
, I-Claim
and I-Claim
PL I-Claim
or I-Claim
between I-Claim
CE I-Claim
and I-Claim
THC I-Claim
at I-Claim
the I-Claim
dosages I-Claim
investigated I-Claim
. I-Claim

The O
findings O
were O
not O
explained O
by O
differences O
in O
adherence O
. O

Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P=0.12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ-MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P=0.086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

Switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim

The O
QoL O
was O
evaluated O
by O
the O
Spitzer O
QL-Index O
and O
by O
the O
EORTC O
QLQ-C30+LC O
13 O
questionnaires O
before O
chemotherapy O
, O
after O
one O
cycle O
, O
after O
three O
cycles O
, O
and O
then O
every O
6 O
weeks O
in O
the O
first O
6 O
months O
and O
every O
3 O
months O
thenafter O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1.01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.77 I-Premise
to I-Premise
1.32 I-Premise
) I-Premise
. I-Premise

From O
May O
1999 O
to O
December O
2004 O
, O
patients O
with O
breast O
cancer O
< O
or O
3 O
cm O
were O
randomly O
assigned O
to O
receive O
SLN O
biopsy O
associated O
with O
ALND O
( O
ALND O
arm O
) O
or O
SLN O
biopsy O
followed O
by O
ALND O
only O
if O
the O
SLN O
was O
metastatic O
( O
SLN O
arm O
) O
. O

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
QOL I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
in I-Premise
the I-Premise
combined I-Premise
community I-Premise
locations I-Premise
relative I-Premise
to I-Premise
hospital I-Premise
( I-Premise
difference I-Premise
of I-Premise
-7.2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
: I-Premise
-19Â·5 I-Premise
to I-Premise
+5Â·2 I-Premise
, I-Premise
P=0.25 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
PB I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
FACT-B I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Breast I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
Social/Family I-Premise
Well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
.041 I-Premise
) I-Premise
, I-Premise
and I-Premise
Breast I-Premise
Cancer-Additional I-Premise
Concerns I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
no I-Claim
dose-dependent I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Mean B-Premise
( I-Premise
s.d I-Premise
. I-Premise
) I-Premise
pain I-Premise
scores I-Premise
on I-Premise
the I-Premise
day I-Premise
of I-Premise
discharge I-Premise
were I-Premise
1Â·9 I-Premise
( I-Premise
3Â·1 I-Premise
) I-Premise
in I-Premise
the I-Premise
epidural I-Premise
group I-Premise
and I-Premise
0Â·7 I-Premise
( I-Premise
0Â·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
WIC I-Premise
group I-Premise
. I-Premise

Standard B-Claim
chemotherapy I-Claim
was I-Claim
superior I-Claim
to I-Claim
capecitabine I-Claim
in I-Claim
improving I-Claim
relapse-free I-Claim
and I-Claim
overall I-Claim
survival I-Claim
for I-Claim
older I-Claim
women I-Claim
with I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
QoL I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
P I-Premise
â‰¤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
diarrhea I-Premise
occurred I-Premise
in I-Premise
36 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
in I-Premise
19 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

Results O
Baseline O
prognostic O
data O
were O
equally O
distributed O
in O
the O
treatment O
groups O
. O

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
more I-Premise
than I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

After O
treatment O
arm O
was O
controlled O
for O
, O
MSTS O
change O
scores O
were O
predicted O
by O
a O
lower-extremity O
tumor O
, O
a O
large O
resection O
specimen O
, O
and O
motor O
nerve O
sacrifice O
";" O
TESS O
change O
scores O
were O
predicted O
by O
lower-extremity O
tumor O
and O
prior O
incomplete O
excision O
. O

Assessments O
were O
performed O
before O
TRT O
and O
until O
week O
54 O
. O

The O
laser O
group O
received O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He-Ne O
, O
Î» O
= O
632.8 O
nm O
, O
power O
density O
= O
24 O
mW/cm O
( O
2 O
) O
, O
dosage O
= O
3.0 O
J O
at O
each O
point O
, O
total O
dose/session O
= O
36-40 O
J O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time/point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O

This O
phase O
III O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy-naive O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

One O
hundred O
seventy-four O
patients O
were O
enrolled O
. O

Seventy-eight O
and O
54 O
% O
of O
C3 O
and O
C6 O
patients O
, O
respectively O
, O
completed O
all O
scheduled O
chemotherapy O
courses O
. O

Anaemia O
is O
common O
in O
patients O
receiving O
chemotherapy O
, O
causing O
symptoms O
that O
have O
a O
major O
impact O
on O
quality O
of O
life O
( O
QoL O
) O
. O

No B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
GP I-Premise
group I-Premise
. I-Premise

573 O
patients O
with O
newly O
diagnosed O
glioblastoma O
were O
randomly O
allocated O
either O
radiotherapy O
alone O
or O
radiotherapy O
and O
temozolomide O
. O

Forty O
patients O
were O
assessable O
for O
toxicity O
and O
32 O
for O
treatment O
response O
. O

Chemotherapy-naÃ¯ve O
patients O
with O
measurable O
unresectable O
and/or O
metastatic O
gastric O
carcinoma O
, O
a O
performance O
status O
< O
or= O
1 O
, O
and O
adequate O
hematologic O
, O
hepatic O
, O
and O
renal O
function O
randomly O
received O
< O
or= O
eight O
3-weekly O
cycles O
of O
ECF O
( O
epirubicin O
50 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
cisplatin O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
and O
fluorouracil O
[ O
FU O
] O
200 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
21 O
) O
, O
TC O
( O
docetaxel O
initially O
85 O
mg/m O
( O
2 O
) O
on O
day O
1 O
[ O
later O
reduced O
to O
75 O
mg/m O
( O
2 O
) O
as O
a O
result O
of O
toxicity O
] O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
or O
TCF O
( O
TC O
plus O
FU O
300 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
14 O
) O
. O

Eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ECOG O
performance O
status O
of O
0 O
to O
2 O
";" O
stable O
brain O
metastases O
were O
allowed O
. O

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O

We O
investigated O
whether O
dignity O
therapy O
could O
mitigate O
distress O
or O
bolster O
the O
experience O
in O
patients O
nearing O
the O
end O
of O
their O
lives O
. O

The O
trial O
was O
closed O
early O
due O
to O
slow O
accrual O
. O

Following O
pretesting O
in O
313 O
patients O
, O
patients O
who O
needed O
district O
nursing O
and O
who O
did O
not O
need O
district O
nursing O
at O
home O
were O
randomly O
assigned O
to O
a O
control O
or O
intervention O
group O
. O

This O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg/m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O

To O
analyze O
the O
predictive O
value O
of O
PSA O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
metastatic O
prostate O
cancer O
. O

Patients O
were O
assessed O
before O
and O
after O
completing O
the O
intervention O
and O
2 O
months O
postintervention O
. O

Extrapolations B-Claim
from I-Claim
these I-Claim
data I-Claim
suggest I-Claim
that I-Claim
radiotherapy I-Claim
may I-Claim
not I-Claim
be I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
unless I-Claim
it I-Claim
results I-Claim
in I-Claim
a I-Claim
recurrence I-Claim
rate I-Claim
that I-Claim
is I-Claim
at I-Claim
least I-Claim
5 I-Claim
% I-Claim
lower I-Claim
in I-Claim
absolute I-Claim
terms I-Claim
than I-Claim
those I-Claim
treated I-Claim
without I-Claim
radiotherapy I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
substantial I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
Spitzer I-Premise
's I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
and I-Premise
for I-Premise
each I-Premise
item I-Premise
. I-Premise

Body O
image O
and O
QOL O
also O
were O
assessed O
preoperatively O
. O

This O
double-blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
Denmark O
, O
Norway O
, O
and O
Sweden O
. O

Cox B-Premise
regression I-Premise
models I-Premise
that I-Premise
took I-Premise
TNM I-Premise
staging I-Premise
or I-Premise
the I-Premise
residual I-Premise
tumor I-Premise
classification I-Premise
and I-Premise
tumor I-Premise
site I-Premise
into I-Premise
account I-Premise
also I-Premise
found I-Premise
significant I-Premise
differences I-Premise
at I-Premise
10 I-Premise
years I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
patients I-Premise
maintained/improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single-item I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
.02 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G3 I-Premise
, I-Premise
QoL I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

For B-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Months I-Premise
over I-Premise
24 I-Premise
months I-Premise
( I-Premise
QALM-24 I-Premise
) I-Premise
was I-Premise
9.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
8.7 I-Premise
, I-Premise
11.2 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.6 I-Premise
, I-Premise
10.5 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise

Patients O
were O
randomized O
to O
receive O
MVP O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Cisplatin O
100 O
mg/m2 O
d1 O
) O
or O
MVC O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Carboplatin O
300 O
mg/m2 O
d1 O
) O
every O
3 O
weeks O
. O

Control O
subjects O
received O
routine O
hospital O
care O
without O
any O
music O
therapy O
intervention O
. O

Cross-sectional B-Premise
comparisons I-Premise
showed I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
some I-Premise
domains/items I-Premise
at I-Premise
specific I-Premise
assessment I-Premise
times I-Premise
with I-Premise
all I-Premise
differences I-Premise
favoring I-Premise
the I-Premise
DOX I-Premise
alone I-Premise
arm I-Premise
. I-Premise

Patients O
( O
n O
= O
429 O
) O
were O
randomly O
assigned O
to O
receive O
doxorubicin O
50 O
mg/m O
( O
2 O
) O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
( O
n O
= O
214 O
) O
or O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
( O
n O
= O
215 O
) O
on O
day O
1 O
, O
every O
3 O
weeks O
for O
up O
to O
eight O
cycles O
. O

Previously O
untreated O
stage O
III O
to O
IVB O
NPC O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg/m O
( O
2 O
) O
/wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
CRT O
alone O
. O

This O
Phase O
II O
, O
open-label O
study O
was O
conducted O
to O
confirm O
the O
activity O
of O
SGN-15 O
plus O
docetaxel O
in O
previously O
treated O
NSCLC O
patients O
. O

At O
a O
median O
of O
2.7 O
years O
after O
surgery O
, O
46 O
patients O
returned O
the O
questionnaires O
regarding O
body O
image O
, O
cosmesis O
, O
and O
morbidity O
. O

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
prospective O
clinical O
study O
received O
institutional O
review O
board O
approval O
. O

Over O
30 O
% O
of O
patients O
with O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
develop O
brain O
metastases O
. O

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
not I-Premise
statistically I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Malignant B-Claim
pleural I-Claim
effusion I-Claim
( I-Claim
MPE I-Claim
) I-Claim
is I-Claim
a I-Claim
common I-Claim
complication I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

For O
those O
reporting O
sexual O
activity O
at O
baseline O
( O
N=41 O
) O
, O
sexual O
dysfunction O
was O
associated O
with O
a O
range O
of O
specific O
measures O
of O
psychological O
well-being O
, O
all O
in O
the O
hypothesized O
direction O
. O

Nonsignificant B-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
found I-Premise
for I-Premise
all I-Premise
unmet I-Premise
supportive I-Premise
care I-Premise
need I-Premise
and I-Premise
quality-of-life I-Premise
scores I-Premise
, I-Premise
change I-Premise
scores I-Premise
, I-Premise
and I-Premise
trends I-Premise
. I-Premise

Trained B-Premise
versus I-Premise
control I-Premise
patients I-Premise
reported I-Premise
reduced I-Premise
barriers I-Premise
to I-Premise
pain I-Premise
relief I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
lower I-Premise
usual I-Premise
pain I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
opioid I-Premise
use I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
, I-Premise
55 I-Premise
% I-Premise
and I-Premise
39 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
( I-Premise
SCL-20 I-Premise
) I-Premise
from I-Premise
baseline I-Premise
compared I-Premise
to I-Premise
34 I-Premise
% I-Premise
and I-Premise
20 I-Premise
% I-Premise
of I-Premise
usual I-Premise
care I-Premise
participants I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.029 I-Premise
) I-Premise
. I-Premise

The B-Premise
dose-intensified I-Premise
arm I-Premise
was I-Premise
slightly I-Premise
more I-Premise
emetogenic I-Premise
and I-Premise
generated I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
but I-Premise
less I-Premise
febrile I-Premise
neutropenia I-Premise
episodes I-Premise
. I-Premise

The B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim

186 O
previously O
untreated O
eligible O
patients O
entered O
the O
study O
. O

An O
outcome O
of O
noninferiority O
of O
short-term O
androgen O
suppression O
as O
compared O
with O
long-term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1.35 O
for O
overall O
survival O
, O
with O
a O
one-sided O
alpha O
level O
of O
0.05 O
. O

All B-Claim
the I-Claim
three I-Claim
opioids I-Claim
used I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
were I-Claim
effective I-Claim
, I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
required I-Claim
similar I-Claim
amounts I-Claim
of I-Claim
symptomatic I-Claim
drugs I-Claim
or I-Claim
co-analgesics I-Claim
. I-Claim

A O
secondary O
criterion O
for O
ablation O
, O
an O
rhTSH-stimulated O
serum O
thyroglobulin O
concentration O
less O
than O
2 O
ng/ml O
, O
was O
fulfilled O
by O
23 O
of O
24 O
( O
96 O
% O
) O
euthyroid O
patients O
and O
18 O
of O
21 O
( O
86 O
% O
) O
hypothyroid O
patients O
( O
P O
= O
0.2341 O
) O
. O

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
women I-Premise
treated I-Premise
with I-Premise
160 I-Premise
mg/d I-Premise
reported I-Premise
less I-Premise
severe I-Premise
side I-Premise
effects I-Premise
( I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
better I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
FLS I-Premise
, I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
less I-Premise
psychologic I-Premise
distress I-Premise
( I-Premise
MHI I-Premise
, I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FLIC I-Premise
, I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
from I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
as I-Premise
compared I-Premise
with I-Premise
those I-Premise
treated I-Premise
with I-Premise
1,600 I-Premise
mg/d I-Premise
. I-Premise

Pain B-Premise
and I-Premise
analgesic I-Premise
scores I-Premise
increased I-Premise
more I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
, I-Premise
but O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
disease I-Premise
progression I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
or I-Premise
quality-of-life I-Premise
scores I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

Adjuvant B-Claim
immunotherapy I-Claim
with I-Claim
whole-cell I-Claim
lysate I-Claim
dendritic I-Claim
cell I-Claim
vaccine I-Claim
may I-Claim
improve I-Claim
short-term I-Claim
survival I-Claim
. I-Claim

Symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
randomly I-Premise
assigned I-Premise
to I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
symptoms I-Premise
of I-Premise
depression I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
health-related I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
( I-Premise
i.e I-Premise
. I-Premise
better I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
and I-Premise
physical I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
less I-Premise
insomnia I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
controls I-Premise
. I-Premise

Few O
well-designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

and O
What O
does O
the O
study O
add O
? O

Adjusted O
linear O
mixed-model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
QoL O
response O
( O
P= O
.005 O
) O
. O

Statistical O
tests O
were O
two-sided O
. O

Leucovorin B-Claim
increases I-Claim
PFS I-Claim
if I-Claim
added I-Claim
to I-Claim
FU24h I-Claim
, I-Claim
but I-Claim
increases I-Claim
toxicity I-Claim
. I-Claim

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

After O
initial O
response O
to O
anthracycline- O
or O
taxane-based O
induction O
chemotherapy O
, O
224 O
patients O
were O
randomly O
assigned O
: O
112 O
to O
high-dose O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
carboplatin O
chemotherapy O
and O
ASCT O
( O
HDCT O
) O
, O
and O
112 O
to O
standard O
therapy O
( O
ST O
) O
. O

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
18.2 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
18.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
0.97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.85 I-Premise
to I-Premise
1.10 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.688 I-Premise
) I-Premise
. I-Premise

Men B-Premise
with I-Premise
prostate I-Premise
cancer I-Premise
and I-Premise
their I-Premise
spouses I-Premise
reported I-Premise
positive I-Premise
outcomes I-Premise
from I-Premise
a I-Premise
family I-Premise
intervention I-Premise
that I-Premise
offered I-Premise
them I-Premise
information I-Premise
and I-Premise
support I-Premise
. I-Premise

The B-Premise
clinical I-Premise
results I-Premise
found I-Premise
raltitrexed I-Premise
and I-Premise
cisplatin I-Premise
to I-Premise
be I-Premise
superior I-Premise
to I-Premise
cisplatin I-Premise
with I-Premise
regard I-Premise
to I-Premise
overall I-Premise
survival I-Premise
( I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

No O
caregiver O
variables O
changed O
, O
which O
may O
indicate O
a O
need O
for O
a O
focus O
on O
caregivers O
. O

Of O
698 O
patients O
available O
for O
intention-to-treat O
analysis O
, O
233 O
were O
assigned O
to O
receive O
vinorelbine O
, O
233 O
to O
gemcitabine O
, O
and O
232 O
to O
vinorelbine O
plus O
gemcitabine O
. O

Patients B-Premise
on I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
had I-Premise
median I-Premise
survivals I-Premise
of I-Premise
31.4 I-Premise
and I-Premise
25.3 I-Premise
weeks I-Premise
, I-Premise
12-month I-Premise
survivals I-Premise
of I-Premise
29 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
, I-Premise
and I-Premise
18-month I-Premise
survivals I-Premise
of I-Premise
18 I-Premise
% I-Premise
and I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. O

To O
compare O
the O
outcomes O
of O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
with O
use O
of O
tris-acryl O
gelatin O
microspheres O
( O
TAGM O
) O
versus O
spherical O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
. O

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

The O
present O
study O
aimed O
to O
compare O
FUP O
with O
5-FU O
alone O
, O
which O
was O
the O
control O
arm O
in O
former O
Mayo O
Clinic O
trials O
. O

Swallowing O
function O
was O
assessed O
with O
the O
Functional O
Oral O
Intake O
Scale O
( O
FOIS O
) O
and O
the O
Performance O
Status O
Scale O
for O
Head O
and O
Neck O
Cancer O
Patients O
( O
PSS-H O
& O
N O
) O
at O
baseline O
, O
immediately O
after O
CRT O
, O
and O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
CRT O
. O

The O
baseline O
characteristics O
( O
with O
the O
exception O
of O
site O
of O
metastases O
) O
were O
balanced O
among O
patients O
with O
CR/PR O
, O
SD O
( O
6m O
) O
, O
and O
progressive O
disease O
( O
PD O
) O
. O

Forty O
were O
not O
eligible O
for O
randomization O
, O
and O
58 O
patients O
were O
randomly O
assigned O
, O
32 O
and O
26 O
patients O
in O
the O
INT O
and O
CONT O
arms O
, O
respectively O
. O

Outcomes O
were O
lymphoedema O
volume O
, O
pain O
, O
heaviness O
and O
tightness O
, O
and O
health-related O
quality O
of O
life O
measured O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
Questionnaire O
for O
Breast O
Cancer O
version O
4 O
( O
FACT-B+4 O
) O
. O

The O
potential O
long-term O
advantages O
of O
LRP O
over O
ORP O
remain O
to O
be O
determined O
. O

However O
, O
these O
guidelines O
can O
be O
questioned O
with O
regard O
to O
the O
extent O
of O
efficacy O
as O
well O
as O
the O
rationale O
for O
not O
using O
strong O
opioids O
as O
first-line O
treatment O
, O
especially O
in O
terminal O
cancer O
patients O
. O

Quality O
of O
life O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
( O
EORTC-C30 O
) O
questionnaire O
. O

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

Among O
all O
participants O
, O
the O
mean O
number O
of O
logins O
over O
8 O
weeks O
was O
20.8 O
Â± O
17.7 O
logins O
for O
the O
III O
+ O
ISG O
compared O
with O
12.5 O
Â± O
12.5 O
in O
III-only O
( O
p O
= O
0.15 O
) O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

This O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
ISRCTN01534787 O
. O

To O
determine O
functional O
and O
psychological O
benefits O
of O
a O
12 O
week O
supervised O
group O
exercise O
programme O
during O
treatment O
for O
early O
stage O
breast O
cancer O
, O
with O
six O
month O
follow-up O
. O

To O
determine O
the O
immediate O
and O
long-term O
effects O
of O
TRUE O
acupuncture O
versus O
sham O
acupuncture O
on O
hot O
flash O
frequency O
in O
women O
with O
breast O
cancer O
. O

The B-Claim
effects I-Claim
of I-Claim
Pemetrexed I-Claim
and I-Claim
Gefitinib I-Claim
as I-Claim
second I-Claim
line I-Claim
therapy I-Claim
were I-Claim
similar I-Claim
, I-Claim
although B-Premise
with I-Premise
different I-Premise
AEs I-Premise
. I-Premise

To O
evaluate O
the O
efficacy O
of O
a O
psychoeducational O
intervention O
in O
improving O
cancer-related O
fatigue O
. O

Sixty-four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O

The B-Premise
response I-Premise
rate I-Premise
in I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
( I-Premise
n=75 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
n=77 I-Premise
) I-Premise
( I-Premise
25.3 I-Premise
% I-Premise
vs. I-Premise
11.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

Oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5-FU I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
for I-Premise
gemcitabine-carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
7.9-9.7 I-Premise
months I-Premise
) I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5.2-7.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0.72 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.58-0.90 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0032 I-Premise
] I-Premise
) I-Premise
. I-Premise

Multivariate O
analyses O
were O
performed O
for O
both O
OS O
and O
LRC O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.2 I-Premise
to I-Premise
15.0 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
13.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.4 I-Premise
to I-Premise
15.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13.7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.0 I-Premise
to I-Premise
16.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.724 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
34 I-Premise
and I-Premise
33.7 I-Premise
months I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.68 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
5-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
and I-Premise
51 I-Premise
% I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.94 I-Premise
) I-Premise
. I-Premise

This O
randomized O
, O
multicenter O
, O
phase O
III O
study O
compared O
doxorubicin O
and O
docetaxel O
( O
AT O
) O
with O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
as O
first-line O
chemotherapy O
( O
CT O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

Hypnosis B-Claim
appears I-Claim
to I-Claim
reduce I-Claim
perceived I-Claim
hot I-Claim
flashes I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
may I-Claim
have I-Claim
additional I-Claim
benefits I-Claim
such I-Claim
as I-Claim
reduced I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
, I-Claim
and I-Claim
improved I-Claim
sleep I-Claim
. I-Claim

The B-Claim
magnitude I-Claim
of I-Claim
improvement I-Claim
obtained I-Claim
was I-Claim
similar I-Claim
whether I-Claim
on I-Claim
a I-Claim
self-declared-healer- I-Claim
or I-Claim
an I-Claim
actor-provided I-Claim
" I-Claim
treatment I-Claim
" I-Claim
. I-Claim

This O
study O
provides O
prospective O
data O
on O
how O
multiple O
dosing O
regimens O
available O
with O
darbepoetin O
alfa O
can O
be O
synchronized O
with O
chemotherapy O
administered O
across O
a O
range O
of O
dosing O
schedules O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Patients B-Claim
with I-Claim
low I-Claim
PSA I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
IAD I-Claim
compared I-Claim
with I-Claim
CAD I-Claim
. I-Claim

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
was I-Premise
321 I-Premise
days I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
was I-Premise
not I-Premise
reached I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
363 I-Premise
days I-Premise
for I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.491 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
. I-Premise

HRQOL B-Claim
was I-Claim
better I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
treated I-Claim
with I-Claim
tamoxifen I-Claim
than I-Claim
those I-Claim
treated I-Claim
with I-Claim
exemestane I-Claim
or I-Claim
anastrozole I-Claim
. I-Claim

A B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r-HuEPO I-Premise
vs. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1.20 I-Premise
units I-Premise
r-HuEPO I-Premise
vs. I-Premise
2.02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r-HuEPO I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise

The O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
impact O
on O
QoL O
, O
substituting O
cisplatin O
, O
a O
pivot O
drug O
in O
NSCLC O
therapy O
, O
with O
carboplatin O
, O
an O
analogue O
with O
an O
improved O
toxicity O
profile O
. O

Sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
is I-Claim
associated I-Claim
with I-Claim
reduced I-Claim
arm I-Claim
morbidity I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
than I-Claim
standard I-Claim
axillary I-Claim
treatment I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
patients I-Claim
who I-Claim
have I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
with I-Claim
clinically I-Claim
negative I-Claim
nodes I-Claim
. I-Claim

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
prophylactic I-Premise
alpha-blockers I-Premise
resulted I-Premise
in I-Premise
statistically I-Premise
lower I-Premise
maximum I-Premise
dysuria I-Premise
scores I-Premise
, I-Premise
while B-Premise
the I-Premise
maximum I-Premise
IPSS I-Premise
after I-Premise
implantation I-Premise
and I-Premise
isotope I-Premise
type I-Premise
( I-Premise
but I-Premise
only I-Premise
at I-Premise
6 I-Premise
months I-Premise
) I-Premise
were I-Premise
the I-Premise
best I-Premise
predictors I-Premise
of I-Premise
the I-Premise
resolution I-Premise
of I-Premise
dysuria I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single-agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Patients O
with O
HER2-positive O
MBC O
whose O
disease O
progressed O
during O
prior O
trastuzumab-based O
therapies O
were O
randomly O
assigned O
to O
receive O
lapatinib O
monotherapy O
or O
lapatinib O
in O
combination O
with O
trastuzumab O
. O

Compared B-Premise
with I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
mean I-Premise
difference I-Premise
scores I-Premise
between I-Premise
the I-Premise
baseline I-Premise
( I-Premise
T1 I-Premise
) I-Premise
and I-Premise
immediate I-Premise
after I-Premise
the I-Premise
test I-Premise
( I-Premise
T2 I-Premise
) I-Premise
assessments I-Premise
increased I-Premise
significantly I-Premise
more I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
for I-Premise
worst I-Premise
and I-Premise
average I-Premise
fatigue I-Premise
, I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Fatigue I-Premise
, I-Premise
and I-Premise
Piper I-Premise
fatigue I-Premise
severity I-Premise
and I-Premise
interference I-Premise
measures I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
patients I-Premise
was I-Premise
15 I-Premise
months I-Premise
, I-Premise
with I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
=.26 I-Premise
) I-Premise
. I-Premise

Based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8-week O
lean O
body O
mass O
between O
the O
two O
arms O
. O

Kaplan-Meier B-Premise
survival I-Premise
curves I-Premise
demonstrated I-Premise
better I-Premise
survival I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
than I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

The O
study O
group O
joined O
a O
weekly O
session O
of O
ALT O
for O
3 O
months O
in O
addition O
to O
the O
self-management O
therapy O
. O

If O
CA125 O
concentration O
exceeded O
twice O
the O
upper O
limit O
of O
normal O
, O
patients O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
minimisation O
to O
early O
or O
delayed O
chemotherapy O
. O

Patients O
randomly O
received O
docetaxel O
60 O
mg/m2 O
( O
day O
1 O
) O
or O
vinorelbine O
25 O
mg/m2 O
( O
days O
1 O
and O
8 O
) O
every O
21 O
days O
for O
four O
cycles O
. O

A B-Premise
convergence I-Premise
of I-Premise
biobehavioral I-Premise
effects I-Premise
and I-Premise
health I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
. I-Premise

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rates I-Premise
, I-Premise
which I-Premise
were I-Premise
confirmed I-Premise
by I-Premise
an I-Premise
independent I-Premise
expert I-Premise
panel I-Premise
, I-Premise
were I-Premise
13 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
% I-Premise
to I-Premise
23.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
27 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
14.1 I-Premise
% I-Premise
to I-Premise
40.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
40 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
25.7 I-Premise
% I-Premise
to I-Premise
54.3 I-Premise
% I-Premise
) I-Premise
for I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Studies O
have O
shown O
that O
there O
is O
a O
high O
prevalence O
of O
depression O
in O
cancer O
patients O
. O

Surgical O
resection O
is O
regarded O
as O
the O
only O
curative O
option O
for O
resectable O
oesophageal O
cancer O
, O
but O
pulmonary O
complications O
occurring O
in O
more O
than O
half O
of O
patients O
after O
open O
oesophagectomy O
are O
a O
great O
concern O
. O

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
radiotherapy I-Claim
and I-Claim
5-fluorouracil I-Claim
changed I-Claim
only I-Claim
some I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
did I-Claim
not I-Claim
have I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

A B-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
including I-Claim
high I-Claim
and I-Claim
low I-Claim
intensity I-Claim
components I-Claim
was I-Claim
feasible I-Claim
and I-Claim
could I-Claim
safely I-Claim
be I-Claim
used I-Claim
in I-Claim
patients I-Claim
with I-Claim
various I-Claim
cancers I-Claim
who I-Claim
were I-Claim
receiving I-Claim
adjuvant I-Claim
chemotherapy I-Claim
or I-Claim
treatment I-Claim
for I-Claim
advanced I-Claim
disease I-Claim
. I-Claim

The O
training O
group O
followed O
an O
8-week O
exercise O
program O
consisting O
of O
3 O
weekly O
sessions O
of O
90-min O
duration O
, O
supervised O
by O
an O
experienced O
investigator O
and O
divided O
into O
resistance O
exercises O
and O
aerobic O
training O
. O

Primary O
objectives O
were O
to O
record O
changes O
from O
baseline O
KP O
and O
to O
assess O
symptom O
palliation O
. O

Sexual B-Premise
functioning I-Premise
was I-Premise
worse I-Premise
for I-Premise
women I-Premise
who I-Premise
received I-Premise
chemotherapy I-Premise
than I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
regardless I-Premise
of I-Premise
type I-Premise
of I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Beyond B-Premise
tumor I-Premise
and I-Premise
nodal I-Premise
stage I-Premise
, I-Premise
Karnofsky I-Premise
performance I-Premise
status I-Premise
, I-Premise
primary I-Premise
site I-Premise
, I-Premise
cigarette I-Premise
use I-Premise
, I-Premise
use I-Premise
of I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
and I-Premise
altered I-Premise
fractionation I-Premise
schedules I-Premise
, I-Premise
the I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
";" I-Premise
N I-Premise
score I-Premise
was I-Premise
independently I-Premise
predictive I-Premise
of I-Premise
LRC I-Premise
( I-Premise
but I-Premise
not I-Premise
OS I-Premise
) I-Premise
, I-Premise
with I-Premise
p I-Premise
= I-Premise
0.0038 I-Premise
. I-Premise

Intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
rates I-Premise
of I-Premise
depression I-Premise
treatment I-Premise
( I-Premise
72.3 I-Premise
% I-Premise
v I-Premise
10.4 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
better I-Premise
quality-of-life I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
social/family I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
, I-Premise
2.7 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.22 I-Premise
to I-Premise
4.17 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
emotional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.29 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26 I-Premise
to I-Premise
2.22 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.34 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.08 I-Premise
to I-Premise
2.59 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
2.79 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.49 I-Premise
to I-Premise
5.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Comparison O
of O
Faslodex O
in O
Recurrent O
or O
Metastatic O
Breast O
Cancer O
( O
CONFIRM O
) O
is O
a O
double-blind O
, O
parallel-group O
, O
multicenter O
, O
phase O
III O
study O
. O

At O
the O
last O
follow-up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

Patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy-induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim

Attrition B-Premise
rates I-Premise
did I-Premise
not I-Premise
vary I-Premise
significantly I-Premise
between I-Premise
study I-Premise
arms I-Premise
. I-Premise

Tumor O
treatment O
was O
unrestricted O
. O

Depression B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
linear I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.019 I-Premise
) I-Premise
, I-Premise
with I-Premise
decreases I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

The B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
C3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
3.9 I-Premise
years I-Premise
, I-Premise
the I-Premise
estimated I-Premise
4-year I-Premise
recurrence-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
67.5 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
62.7 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.19 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.095 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

QUARTZ O
is O
a O
randomised O
, O
non-inferiority O
, O
phase O
III O
trial O
comparing O
OSC O
+ O
WBRT O
versus O
OSC O
in O
patients O
with O
inoperable O
brain O
metastases O
from O
NSCLC O
. O

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

QOL O
information O
, O
using O
validated O
instruments O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
[ O
FACT-L O
] O
, O
version O
2 O
, O
and O
Functional O
Living O
Index-Cancer O
[ O
FLIC O
] O
) O
, O
was O
prospectively O
collected O
in O
patients O
with O
locally O
advanced O
NSCLC O
treated O
on O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
trial O
89-01 O
. O

The O
secondary O
endpoints O
included O
patient O
reported O
outcome O
measures O
";" O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
, O
Sleep O
disturbances O
( O
MOS-sleep O
questionnaire O
) O
and O
symptoms O
from O
the O
irradiated O
area O
( O
visual O
analogue O
scale O
) O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
8 I-Premise
years I-Premise
, I-Premise
the I-Premise
5-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
68 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
3 I-Premise
% I-Premise
standard I-Premise
error I-Premise
of I-Premise
the I-Premise
mean I-Premise
( I-Premise
SEM I-Premise
) I-Premise
and I-Premise
the I-Premise
5-year I-Premise
event-free I-Premise
survival I-Premise
53 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
4 I-Premise
% I-Premise
SEM I-Premise
) I-Premise
. I-Premise

However B-Claim
, I-Claim
the I-Claim
intervention I-Claim
was I-Claim
not I-Claim
found I-Claim
to I-Claim
reduce I-Claim
the I-Claim
risk I-Claim
of I-Claim
cancer I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
. I-Claim

The B-Premise
patients I-Premise
reported I-Premise
low I-Premise
levels I-Premise
of I-Premise
skin I-Premise
related I-Premise
symptoms I-Premise
and I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
groups I-Premise
were I-Premise
found I-Premise
. I-Premise

Postmenopausal O
women O
with O
hormone O
receptor-positive O
breast O
cancer O
( O
N=5,187 O
) O
were O
randomized O
to O
letrozole O
2.5 O
mg O
or O
placebo O
once O
daily O
for O
5 O
years O
. O

Treatment B-Premise
was I-Premise
associated I-Premise
with I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
( I-Premise
P=.024 I-Premise
) I-Premise
and I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

ES B-Premise
scores I-Premise
and I-Premise
CES-D I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Dominant O
fibroid O
diameter O
, O
uterine O
volume O
, O
total O
fibroid O
infarction O
( O
complete O
100 O
% O
, O
almost O
complete O
90-99 O
% O
, O
partial O
< O
90 O
% O
) O
, O
and O
new O
fibroid O
formation O
were O
the O
main O
parameters O
assessed O
and O
related O
to O
the O
need O
for O
reintervention O
. O

Patients O
had O
a O
free O
choice O
of O
treosulfan O
i.v O
. O

Proinflammatory O
cytokines O
, O
especially O
tumour O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
, O
play O
a O
prominent O
role O
in O
the O
pathogenesis O
of O
cancer O
cachexia O
. O

After O
16 O
of O
the O
first O
65 O
randomized O
patients O
experienced O
febrile O
neutropenia O
( O
FN O
) O
, O
the O
doses O
were O
reduced O
to O
DOX O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
VNB O
20 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
versus O
DOX O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
. O

The O
aim O
of O
the O
project O
was O
to O
identify O
clinical O
and O
quality O
of O
life O
( O
QL O
) O
factors O
that O
together O
predict O
survival O
and O
response O
to O
chemotherapy O
in O
advanced O
breast O
cancer O
. O

Patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7.6 I-Premise
vs I-Premise
6.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise

Randomisation O
was O
by O
use O
of O
a O
computer-generated O
table O
of O
random O
numbers O
in O
blocks O
of O
30 O
. O

Of O
the O
120 O
participants O
randomly O
assigned O
, O
78 O
( O
65 O
% O
) O
completed O
the O
post-treatment O
assessment O
and O
67 O
( O
56 O
% O
) O
completed O
the O
2-month O
follow-up O
. O

We O
used O
these O
data O
in O
a O
Cox O
proportional O
hazards O
analysis O
to O
examine O
whether O
decreasing O
depression O
symptoms O
over O
the O
first O
year O
of O
the O
study O
( O
the O
length O
of O
the O
intervention O
) O
would O
be O
associated O
with O
longer O
survival O
. O

Median B-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
and I-Premise
placebo I-Premise
was I-Premise
2.7 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
80 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
1.36 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.51 I-Premise
) I-Premise
. I-Premise

Conducted O
in O
small O
groups O
, O
intervention O
sessions O
were O
offered O
weekly O
for O
4 O
months O
and O
followed O
by O
monthly O
sessions O
for O
8 O
months O
. O

We O
compared O
the O
effectiveness O
and O
toxicity O
of O
the O
combination O
of O
vinorelbine O
plus O
gemcitabine O
with O
those O
of O
each O
drug O
given O
alone O
in O
an O
open-label O
, O
randomized O
phase O
III O
trial O
in O
elderly O
patients O
with O
advanced O
NSCLC O
. O

Metastatic B-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
high I-Claim
baseline I-Claim
PSA I-Claim
, I-Claim
pain I-Claim
, I-Claim
and I-Claim
high I-Claim
PSA I-Claim
nadir I-Claim
have I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
with I-Claim
ADT I-Claim
. I-Claim

Median B-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
8.3 I-Premise
, I-Premise
11.0 I-Premise
, I-Premise
and I-Premise
10.4 I-Premise
months I-Premise
for I-Premise
ECF I-Premise
, I-Premise
TC I-Premise
, I-Premise
and I-Premise
TCF I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
primary O
outcome O
was O
self-reported O
total O
exercise O
( O
in O
metabolic O
equivalent O
[ O
MET O
] O
hours O
per O
week O
) O
at O
5 O
weeks O
postconsultation O
. O

Change B-Premise
in I-Premise
self-efficacy I-Premise
for I-Premise
fat I-Premise
restriction I-Premise
partially I-Premise
accounted I-Premise
for I-Premise
the I-Premise
intervention I-Premise
's I-Premise
impact I-Premise
on I-Premise
overall I-Premise
diet I-Premise
quality I-Premise
among I-Premise
men I-Premise
only I-Premise
( I-Premise
mean I-Premise
indirect I-Premise
effect I-Premise
= I-Premise
0.60 I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
response I-Premise
and I-Premise
ORR I-Premise
favor I-Premise
TCF I-Premise
over I-Premise
TC I-Premise
for I-Premise
further I-Premise
evaluation I-Premise
, I-Premise
particularly I-Premise
in I-Premise
the I-Premise
neoadjuvant I-Premise
setting I-Premise
. I-Premise

At O
six O
oncology O
clinics O
, O
physicians O
( O
N=22 O
) O
and O
nurses O
( O
N=23 O
) O
enrolled O
patients O
( O
N=93 O
) O
who O
were O
over O
18 O
years O
of O
age O
, O
with O
cancer O
diagnoses O
, O
pain O
, O
and O
a O
life O
expectancy O
of O
at O
least O
6 O
months O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

During O
the O
3-day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1-3 O
tablets O
of O
oxycodone/paracetamol O
( O
5/325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O

From O
December O
1997 O
through O
February O
2003 O
, O
244 O
men O
with O
newly O
diagnosed O
localized O
prostate O
cancer O
were O
randomly O
assigned O
to O
cryoablation O
or O
EBRT O
( O
median O
dose O
68 O
Gy O
) O
. O

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
4.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
4.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
5.0 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
5.6 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.4 I-Premise
to I-Premise
6.7 I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.029 I-Premise
) I-Premise
. I-Premise

The O
primary O
end O
point O
was O
progression-free O
survival O
. O

No B-Premise
differences I-Premise
in I-Premise
QOL I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0-2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
's O
formula O
, O
equivalent O
to O
Calvert O
's O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
-2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3-week O
cycle O
. O

This O
multicenter O
, O
open-label O
, O
phase O
III O
study O
randomly O
assigned O
patients O
in O
a O
1:2 O
ratio O
to O
irinotecan O
given O
either O
weekly O
( O
125 O
mg/m O
( O
2 O
) O
) O
or O
once O
every O
3 O
weeks O
( O
350 O
mg/m O
( O
2 O
) O
, O
or O
300 O
mg/m O
( O
2 O
) O
in O
patients O
who O
were O
> O
/= O
70 O
years O
of O
age O
, O
who O
had O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
equal O
to O
2 O
, O
or O
who O
had O
prior O
pelvic O
irradiation O
) O
. O

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
except B-Premise
for I-Premise
hair I-Premise
loss I-Premise
. I-Premise

The B-Premise
3-drug I-Premise
combination I-Premise
, I-Premise
supportive I-Premise
care I-Premise
and I-Premise
radiotherapy I-Premise
groups I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
from I-Premise
each I-Premise
other I-Premise
with I-Premise
respect I-Premise
to I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
or I-Premise
its I-Premise
subscales I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

However B-Premise
, I-Premise
raw I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
not I-Premise
different I-Premise
at I-Premise
these I-Premise
time-points I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

To O
test O
this O
hypothesis O
, O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
initiated O
the O
Breast O
Cancer O
Prevention O
Trial O
( O
P-1 O
) O
in O
1992 O
. O

AET B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient-rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
the I-Premise
2-year I-Premise
OS I-Premise
rates I-Premise
were I-Premise
65.7 I-Premise
% I-Premise
for I-Premise
CIS I-Premise
and I-Premise
66.2 I-Premise
% I-Premise
for I-Premise
TPZ/CIS I-Premise
( I-Premise
TPZ/CIS I-Premise
-- I-Premise
CIS I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-5.9 I-Premise
% I-Premise
to I-Premise
6.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
specialized O
supportive O
enteral O
and O
parenteral O
feeding O
have O
superior O
effects O
compared O
to O
oral O
nutrition O
on O
recovery O
during O
long-term O
postoperative O
treatment O
of O
cancer O
patients O
with O
preoperative O
weight O
loss O
and O
reduced O
maximum O
exercise O
capacity O
. O

However B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

At B-Premise
the I-Premise
2-month I-Premise
follow-up I-Premise
assessment I-Premise
, I-Premise
the I-Premise
improvements I-Premise
observed I-Premise
for I-Premise
the I-Premise
IMCP I-Premise
group I-Premise
were I-Premise
no I-Premise
longer I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
those I-Premise
observed I-Premise
for I-Premise
the I-Premise
TM I-Premise
group I-Premise
. I-Premise

In B-Premise
70 I-Premise
evaluable I-Premise
study I-Premise
subjects I-Premise
, I-Premise
the I-Premise
curative I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
found I-Premise
in I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
( I-Premise
83.33 I-Premise
vs. I-Premise
50.00 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti-TNF I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

DC-treated B-Premise
patients I-Premise
experienced I-Premise
improved I-Premise
pain I-Premise
relief I-Premise
compared I-Premise
with I-Premise
VC I-Premise
( I-Premise
P=0.033 I-Premise
) I-Premise
, I-Premise
whereas O
pain B-Premise
relief I-Premise
with I-Premise
DCb I-Premise
and I-Premise
VC I-Premise
was I-Premise
similar I-Premise
. I-Premise

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

The B-Premise
CR I-Premise
rate I-Premise
and I-Premise
the I-Premise
3-year I-Premise
CR I-Premise
duration I-Premise
were I-Premise
not I-Premise
affected I-Premise
adversely I-Premise
by I-Premise
use I-Premise
of I-Premise
epoetin I-Premise
alpha I-Premise
. I-Premise

Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well-being I-Claim
. I-Claim

Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

77 O
adult O
patients O
with O
cancer O
receiving O
moderately O
or O
highly O
emetogenic O
chemotherapy O
agents O
. O

Median B-Premise
survival I-Premise
was I-Premise
16.6 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/bevacizumab I-Premise
group I-Premise
and I-Premise
12.9 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/placebo I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.16 I-Premise
) I-Premise
. I-Premise

Between O
February O
1999 O
and O
August O
2001 O
, O
422 O
patients O
( O
GCa O
, O
n O
= O
212 O
";" O
MIC O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
United O
Kingdom O
. O

A O
total O
of O
173 O
patients O
( O
82 O
% O
of O
the O
expected O
) O
in O
the O
observation O
arm O
and O
186 O
( O
85 O
% O
of O
expected O
) O
in O
the O
chemotherapy O
arm O
completed O
baseline O
QOL O
assessments O
. O

The B-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
for I-Claim
radiation I-Claim
oncology I-Claim
is I-Claim
a I-Claim
useful I-Claim
guide I-Claim
to I-Claim
the I-Claim
level I-Claim
of I-Claim
nutrition I-Claim
support I-Claim
required I-Claim
. I-Claim

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct-switch I-Premise
patients I-Premise
, I-Premise
similar I-Premise
clinically I-Premise
meaningful I-Premise
improvements I-Premise
were I-Premise
seen I-Premise
in I-Premise
DAS28 I-Premise
( I-Premise
CRP I-Premise
) I-Premise
( I-Premise
> I-Premise
or I-Premise
=1.2 I-Premise
unit I-Premise
improvement I-Premise
, I-Premise
59.5 I-Premise
% I-Premise
vs I-Premise
53.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
low I-Premise
disease I-Premise
activity I-Premise
state I-Premise
, I-Premise
22.5 I-Premise
% I-Premise
vs I-Premise
22.3 I-Premise
% I-Premise
";" I-Premise
DAS28-defined I-Premise
remission I-Premise
, I-Premise
12.0 I-Premise
% I-Premise
vs I-Premise
13.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
function I-Premise
( I-Premise
health I-Premise
assessment I-Premise
questionnaire I-Premise
disability I-Premise
index I-Premise
> I-Premise
or I-Premise
=0.22 I-Premise
improvement I-Premise
";" I-Premise
46.3 I-Premise
% I-Premise
vs I-Premise
47.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
mean I-Premise
change I-Premise
in I-Premise
short-form I-Premise
36 I-Premise
scores I-Premise
: I-Premise
physical I-Premise
component I-Premise
summary I-Premise
, I-Premise
5.5 I-Premise
vs I-Premise
6.1 I-Premise
";" I-Premise
mental I-Premise
component I-Premise
summary I-Premise
, I-Premise
4.8 I-Premise
vs I-Premise
5.4 I-Premise
) I-Premise
. I-Premise

Secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression-free O
survival O
time O
. O

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non-responder I-Premise
analyses I-Premise
, I-Premise
ACR I-Premise
responses I-Premise
in I-Premise
abatacept-treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59.4 I-Premise
% I-Premise
and I-Premise
56.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23.5 I-Premise
% I-Premise
and I-Premise
33.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11.5 I-Premise
% I-Premise
and I-Premise
16.1 I-Premise
% I-Premise
";" I-Premise
HAQ-DI I-Premise
responses I-Premise
were I-Premise
54.4 I-Premise
% I-Premise
and I-Premise
47.9 I-Premise
% I-Premise
. I-Premise

However B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer-related I-Claim
fatigue I-Claim
. I-Claim

Secondary O
end O
points O
evaluated O
were O
as O
follows O
: O
clinical O
efficacy O
";" O
quality O
of O
life O
";" O
safety O
";" O
and O
survival O
. O

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
post-randomisation I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
and I-Premise
control I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
arm I-Premise
volume I-Premise
. I-Premise

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

The B-Premise
body I-Premise
image I-Premise
and I-Premise
cosmesis I-Premise
scores I-Premise
of I-Premise
female I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
LRP I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
( I-Premise
body I-Premise
image I-Premise
, I-Premise
17.4 I-Premise
vs I-Premise
14.9 I-Premise
";" I-Premise
cosmesis I-Premise
, I-Premise
19.1 I-Premise
vs I-Premise
13.0 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

To O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p.o O
. O

To O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
'low-risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
T0-2 O
) O
treated O
by O
breast-conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost-effective O
. O

The O
primary O
end-point O
of O
the O
study O
was O
the O
incidence O
of O
Radiation O
Therapy O
Oncology O
Group O
grade O
3 O
mucositis O
. O

The B-Premise
mean I-Premise
quality-adjusted I-Premise
survival I-Premise
was I-Premise
increased I-Premise
by I-Premise
1.8 I-Premise
months I-Premise
in I-Premise
the I-Premise
capecitabine/docetaxel I-Premise
group I-Premise
. I-Premise

Seventy-eight B-Premise
percent I-Premise
of I-Premise
patients I-Premise
expressed I-Premise
satisfaction I-Premise
with I-Premise
their I-Premise
treatment I-Premise
whatever I-Premise
their I-Premise
location I-Premise
, I-Premise
whereas I-Premise
57 I-Premise
% I-Premise
of I-Premise
patients I-Premise
preferred I-Premise
future I-Premise
treatment I-Premise
to I-Premise
continue I-Premise
at I-Premise
the I-Premise
hospital I-Premise
, I-Premise
81 I-Premise
% I-Premise
at I-Premise
GP I-Premise
surgeries I-Premise
and I-Premise
90 I-Premise
% I-Premise
at I-Premise
home I-Premise
. I-Premise

At B-Premise
the I-Premise
six I-Premise
month I-Premise
follow-up I-Premise
, I-Premise
most I-Premise
of I-Premise
these I-Premise
effects I-Premise
were I-Premise
maintained I-Premise
and I-Premise
an I-Premise
intervention I-Premise
effect I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
quality I-Premise
of I-Premise
life I-Premise
emerged I-Premise
. I-Premise

Compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
QoL I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
5.5 I-Premise
months I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.04 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.727 I-Premise
) I-Premise
, I-Premise
while I-Premise
ORR I-Premise
was I-Premise
25 I-Premise
% I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
to I-Premise
EUC I-Premise
, I-Premise
TEC I-Premise
was I-Premise
associated I-Premise
with I-Premise
increased I-Premise
pain I-Premise
communication I-Premise
self-efficacy I-Premise
after I-Premise
the I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
both B-Premise
groups I-Premise
showed I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
similar I-Premise
, I-Premise
reductions I-Premise
in I-Premise
pain I-Premise
misconceptions I-Premise
. I-Premise

We O
have O
compared O
an O
alternating O
regimen O
of O
bolus O
and O
continuous O
infusion O
5-FU O
, O
selectively O
modulated O
for O
the O
schedule O
of O
administration O
, O
with O
modulated O
bolus O
5-FU O
in O
advanced O
colorectal O
cancer O
patients O
. O

The B-Premise
mean I-Premise
cost I-Premise
per I-Premise
QALY I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13,558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise

ARSR B-Claim
seem I-Claim
to I-Claim
be I-Claim
a I-Claim
relatively I-Claim
limited I-Claim
problem I-Claim
, I-Claim
probably I-Claim
more I-Claim
influenced I-Claim
by I-Claim
treatment I-Claim
related I-Claim
factors I-Claim
than I-Claim
by I-Claim
choice I-Claim
of I-Claim
skin I-Claim
care I-Claim
products I-Claim
in I-Claim
this I-Claim
patient I-Claim
group I-Claim
. I-Claim

Four O
hundred O
forty-seven O
patients O
were O
randomly O
assigned O
to O
PCV O
( O
224 O
patients O
) O
or O
TMZ O
( O
sub-random O
assignment O
: O
TMZ-5 O
[ O
200 O
mg/m O
( O
2 O
) O
for O
5 O
days O
, O
112 O
patients O
] O
or O
TMZ-21 O
[ O
100 O
mg/m O
( O
2 O
) O
for O
21 O
days O
, O
111 O
patients O
] O
) O
for O
up O
to O
9 O
months O
or O
until O
progression O
. O

Capecitabine B-Premise
treatment I-Premise
was I-Premise
associated I-Premise
with I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
constipation I-Premise
and I-Premise
with I-Premise
better I-Premise
appetite I-Premise
than I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
â‰¤ I-Premise
.004 I-Premise
) I-Premise
, I-Premise
but I-Premise
worse I-Premise
hand-foot I-Premise
syndrome I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Multicentre O
randomised O
controlled O
trial O
. O

The B-Premise
rate I-Premise
of I-Premise
QOL I-Premise
drop-out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
C I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
CP I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
";" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

Quality O
of O
life O
was O
assessed O
using O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
questionnaire O
. O

Nineteen B-Premise
percent I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
were I-Premise
progression-free I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
compared I-Premise
with I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
alone I-Premise
( I-Premise
P I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Challenges O
with O
capturing O
pain O
data O
were O
identified O
and O
resolved O
. O

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O

Kaposi O
's O
sarcoma O
is O
currently O
the O
most O
common O
tumor O
in O
Zimbabwe O
. O

Ninety-four O
patients O
received O
PB O
, O
and O
93 O
received O
paclitaxel/bevacizumab/gemcitabine O
( O
PB+G O
) O
. O

In B-Premise
QoL I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
PE I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

There B-Claim
were I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
favouring I-Claim
the I-Claim
SNB I-Claim
group I-Claim
throughout I-Claim
the I-Claim
18 I-Claim
months I-Claim
assessment I-Claim
. I-Claim

In O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient-tailored O
treatment O
( O
PPT O
) O
of O
symptoms O
or O
care O
as O
usual O
. O

As B-Premise
hypothesized I-Premise
, I-Premise
Bcl-2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
CRA/IFN I-Premise
therapy I-Premise
only I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Laparoscopic B-Claim
resection I-Claim
reduced I-Claim
length I-Claim
of I-Claim
hospital I-Claim
stay I-Claim
, I-Claim
improved I-Claim
first-year I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
slightly I-Claim
increased I-Claim
hospital I-Claim
costs I-Claim
. I-Claim

The O
relationship O
between O
change O
in O
self-efficacy O
and O
long-term O
physical O
activity O
( O
PA O
) O
also O
was O
examined O
. O

Time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR=0.61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.42-0.88 I-Premise
] I-Premise
";" I-Premise
p=0.0080 I-Premise
and I-Premise
HR=0.66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.46-0.94 I-Premise
] I-Premise
";" I-Premise
p=0.0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

QOL O
evaluations O
were O
available O
for O
199 O
patients O
. O

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
12.1 I-Premise
months I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
B I-Premise
[ I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.85-1.15 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.93 I-Premise
] I-Premise
. I-Premise

Outcomes B-Premise
in I-Premise
the I-Premise
nurse I-Premise
group I-Premise
were I-Premise
not I-Premise
inferior I-Premise
to I-Premise
outcomes I-Premise
in I-Premise
the I-Premise
gastroenterologist I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
1Â·36 I-Premise
, I-Premise
one I-Premise
sided I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1Â·48 I-Premise
) I-Premise
. I-Premise

The B-Premise
improvement I-Premise
in I-Premise
pain-related I-Premise
impairment I-Premise
was I-Premise
not I-Premise
sustained I-Premise
at I-Premise
6 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
. I-Premise

During O
2000-2005 O
, O
two O
concomitant O
chemoradiation O
treatment O
methods O
( O
radiotherapy O
with O
5-fluorouracil O
and O
radiotherapy O
with O
gemcitabine O
) O
were O
analyzed O
in O
the O
study O
. O

No B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3-month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise

Improvement B-Premise
over I-Premise
time I-Premise
and I-Premise
time I-Premise
x I-Premise
treatment I-Premise
effects I-Premise
only I-Premise
reached I-Premise
trend I-Premise
significance I-Premise
levels I-Premise
( I-Premise
ps I-Premise
= I-Premise
0.07 I-Premise
& I-Premise
amp I-Premise
";" I-Premise
0.12 I-Premise
) I-Premise
as I-Premise
this I-Premise
pilot I-Premise
was I-Premise
not I-Premise
powered I-Premise
to I-Premise
detect I-Premise
these I-Premise
differences I-Premise
. I-Premise

Severe B-Premise
HSRs I-Premise
were I-Premise
rare I-Premise
( I-Premise
1.5 I-Premise
% I-Premise
patients I-Premise
) I-Premise
and I-Premise
were I-Premise
not I-Premise
affected I-Premise
by I-Premise
either I-Premise
dose I-Premise
or I-Premise
schedule I-Premise
. I-Premise

To O
further O
evaluate O
EVE O
+ O
EXE O
impact O
on O
disease O
burden O
, O
we O
conducted O
additional O
post-hoc O
analyses O
of O
patient-reported O
HRQOL O
. O

As B-Premise
for I-Premise
the I-Premise
secondary I-Premise
efficacy I-Premise
endpoints I-Premise
, I-Premise
patient I-Premise
appetite I-Premise
increased I-Premise
, I-Premise
and I-Premise
ECOG I-Premise
PS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Prior O
studies O
have O
suggested O
that O
melatonin O
, O
a O
frequently O
used O
integrative O
medicine O
, O
can O
attenuate O
weight O
loss O
, O
anorexia O
, O
and O
fatigue O
in O
patients O
with O
cancer O
. O

Time B-Premise
to I-Premise
progression I-Premise
( I-Premise
TTP I-Premise
";" I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
TTF I-Premise
) I-Premise
were I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
AT I-Premise
than I-Premise
AC I-Premise
( I-Premise
median I-Premise
TTP I-Premise
, I-Premise
37.3 I-Premise
v I-Premise
31.9 I-Premise
weeks I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.014 I-Premise
";" I-Premise
median I-Premise
TTF I-Premise
, I-Premise
25.6 I-Premise
v I-Premise
23.7 I-Premise
weeks I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

Measurements O
were O
performed O
before O
( O
T0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
T1 O
) O
, O
and O
at O
a O
3-month O
follow-up O
( O
T2 O
) O
. O

No B-Premise
significant I-Premise
differences I-Premise
in I-Premise
rates I-Premise
of I-Premise
acute I-Premise
toxicities I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
during I-Premise
CRT I-Premise
. I-Premise

Analysis O
was O
by O
intent O
to O
treat O
. O

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU/LV I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first-line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression-free I-Claim
survival I-Claim
. I-Claim

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
among I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
advantage I-Premise
lasted I-Premise
for I-Premise
all I-Premise
the I-Premise
duration I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

ONJ B-Claim
is I-Claim
multifactorial I-Claim
and I-Claim
no I-Claim
single I-Claim
treatment I-Claim
modality I-Claim
is I-Claim
likely I-Claim
to I-Claim
reverse I-Claim
it I-Claim
";" I-Claim
however B-Claim
, I-Claim
it I-Claim
is I-Claim
treatable I-Claim
and I-Claim
even I-Claim
advanced I-Claim
presentations I-Claim
can I-Claim
improve I-Claim
with I-Claim
intensive I-Claim
multimodal I-Claim
therapy I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
single-fraction I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

This O
study O
is O
the O
first O
large O
prospective O
RCT O
of O
sentinel O
node O
biopsy O
( O
SNB O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
I-III O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
QOL O
) O
assessments O
over O
18 O
months O
. O

We O
conducted O
a O
randomized O
trial O
comparing O
uterine-artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O

Compliance O
with O
QoL O
questionnaires O
was O
88 O
% O
. O

Median B-Premise
PFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
8.2 I-Premise
and I-Premise
19.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
26.4 I-Premise
months I-Premise
. I-Premise

It O
is O
equieffective O
as O
oral O
( O
p.o O
. O
) O

However B-Claim
, I-Claim
many I-Claim
patients I-Claim
develop I-Claim
clinically I-Claim
relevant I-Claim
neurotoxicity I-Claim
, I-Claim
frequently I-Claim
resulting I-Claim
in I-Claim
treatment I-Claim
discontinuation I-Claim
. I-Claim

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

Exploratory O
end O
points O
included O
association O
of O
efficacy O
with O
epidermal O
growth O
factor O
receptor O
gene O
copy O
number O
and O
other O
biomarkers O
. O

To O
examine O
the O
effect O
of O
a O
progressive O
upper-body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O

Venlafaxine O
( O
Effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
P=0.40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise

Vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0.064 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.016-0.112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0.054 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.007-0.102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise

An B-Claim
Internet-based I-Claim
education I-Claim
program I-Claim
based I-Claim
on I-Claim
NCCN I-Claim
guidelines I-Claim
and I-Claim
TTM I-Claim
may I-Claim
help I-Claim
patients I-Claim
manage I-Claim
CRF I-Claim
. I-Claim

Two O
hundred O
and O
ninety-seven O
patients O
were O
randomised O
( O
C3 O
150 O
, O
C6 O
147 O
) O
. O

Docetaxel-carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel-carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow-up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim

After O
four O
cycles O
of O
platinum-based O
induction O
therapy O
, O
663 O
patients O
with O
stage O
IIIB O
or O
stage O
IV O
NSCLC O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
or O
1 O
were O
randomly O
assigned O
( O
in O
a O
2:1 O
ratio O
) O
from O
March O
15 O
, O
2005 O
, O
to O
July O
20 O
, O
2007 O
, O
using O
the O
Pocock O
and O
Simon O
minimisation O
method O
to O
receive O
pemetrexed O
( O
500 O
mg/m O
( O
2 O
) O
every O
21 O
days O
";" O
n=441 O
) O
or O
placebo O
( O
n=222 O
) O
plus O
best O
supportive O
care O
until O
disease O
progression O
. O

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
8.1-10.4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.7-12.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.247 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.82 I-Premise
) I-Premise
";" I-Premise
the I-Premise
median I-Premise
OS I-Premise
was I-Premise
25.0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
18.8-not I-Premise
assessable I-Premise
[ I-Premise
N/A I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
20.3-N/A I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.475 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.84 I-Premise
) I-Premise
, I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A O
well-tolerated O
and O
effective O
mind-body O
treatment O
for O
hot O
flashes O
would O
be O
of O
great O
value O
. O

Data O
were O
analyzed O
with O
use O
of O
t O
tests O
, O
the O
Mann-Whitney O
U O
test O
, O
and O
chi2 O
tests O
as O
appropriate O
. O

An O
EGP O
does O
not O
unequivocally O
affect O
positive O
HRQoL O
outcomes O
. O

However O
, O
in B-Claim
this I-Claim
group I-Claim
of I-Claim
patients I-Claim
treated I-Claim
with I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
lozenge I-Claim
did I-Claim
not I-Claim
impact I-Claim
significantly I-Claim
on I-Claim
the I-Claim
severity I-Claim
of I-Claim
mucositis I-Claim
. I-Claim

We O
explored O
the O
quality O
of O
life O
( O
QoL O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O

Patients O
( O
aged O
â‰¥18 O
years O
) O
with O
a O
terminal O
prognosis O
( O
life O
expectancy O
â‰¤6 O
months O
) O
who O
were O
receiving O
palliative O
care O
in O
a O
hospital O
or O
community O
setting O
( O
hospice O
or O
home O
) O
in O
Canada O
, O
USA O
, O
and O
Australia O
were O
randomly O
assigned O
to O
dignity O
therapy O
, O
client-centred O
care O
, O
or O
standard O
palliative O
care O
in O
a O
1:1:1 O
ratio O
. O

The O
primary O
HRQOL O
scale O
was O
global O
HRQOL O
per O
protocol O
. O

Data O
come O
from O
the O
Moving O
Beyond O
Cancer O
psychoeducational O
intervention O
trial O
, O
aimed O
at O
easing O
the O
transition O
from O
patient O
to O
survivor O
. O

The O
present O
study O
is O
an O
open O
randomized O
clinical O
trial O
comparing O
estramustine O
phosphate O
( O
Estracyt O
) O
in O
addition O
to O
radiotherapy O
with O
radiotherapy O
alone O
as O
first O
line O
treatment O
of O
astrocytoma O
grade O
III O
and O
IV O
. O

They O
were O
randomly O
divided O
to O
receive O
either O
glutamine-enriched O
TPN O
or O
standard O
TPN O
. O

To O
assess O
the O
effect O
of O
a O
multimodal O
group O
exercise O
intervention O
, O
as O
an O
adjunct O
to O
conventional O
care O
, O
on O
fatigue O
, O
physical O
capacity O
, O
general O
wellbeing O
, O
physical O
activity O
, O
and O
quality O
of O
life O
in O
patients O
with O
cancer O
who O
were O
undergoing O
adjuvant O
chemotherapy O
or O
treatment O
for O
advanced O
disease O
. O

G O
responses O
: O
2 O
PR O
( O
5.3 O
% O
) O
and O
16 O
SD O
( O
42.1 O
% O
) O
";" O
DCR O
( O
47.4 O
% O
) O
. O

Sixty-eight O
eligible O
research O
volunteers O
with O
a O
minimum O
20 O
% O
increase O
in O
arm O
volume O
at O
a O
median O
15.5 O
years O
( O
range O
2-41 O
) O
after O
axillary/supraclavicular O
radiotherapy O
( O
plus O
axillary O
surgery O
in O
51/68 O
( O
75 O
% O
) O
cases O
) O
were O
randomised O
to O
active O
drugs O
or O
placebo O
. O

To O
describe O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
review O
and O
approval O
of O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Rehabilitation O
aims O
to O
address O
these O
needs O
, O
maximize O
psychological O
and O
physical O
function O
, O
and O
enable O
minimum O
dependency O
regardless O
of O
life O
expectancy O
. O

This O
difference O
( O
7.4 O
) O
was O
clinically O
relevant O
. O

The O
applicant O
has O
committed O
to O
conduct O
post-marketing O
clinical O
trials O
to O
assess O
further O
the O
effect O
of O
epidermal O
growth O
factor O
receptor O
expression O
, O
measured O
with O
immunohistochemical O
staining O
, O
on O
erlotinib O
treatment O
effect O
. O

After O
a O
median O
follow-up O
of O
5.5 O
years O
, O
277 O
events O
have O
been O
reported O
. O

Functional O
assessment O
of O
cancer O
therapy O
( O
FACT O
) O
questionnaire O
, O
Beck O
depression O
inventory O
, O
positive O
and O
negative O
affect O
scale O
, O
body O
mass O
index O
, O
seven O
day O
recall O
of O
physical O
activity O
, O
12 O
minute O
walk O
test O
, O
and O
assessment O
of O
shoulder O
mobility O
. O

A O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
EOF O
) O
compared O
with O
traditional O
oral O
feeding O
( O
TOF O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O

The O
2-year O
risk O
of O
progression O
for O
baseline O
PSA O
< O
50 O
ng/ml O
, O
50 O
to O
< O
500 O
ng/ml O
, O
and O
â‰¥ O
500 O
ng/ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
P O
= O
0.03 O
) O
in O
CAD O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
P O
= O
0.006 O
) O
in O
IAD O
, O
respectively O
. O

The O
effect O
of O
this O
intervention O
on O
a O
patient O
's O
general O
well-being O
was O
also O
investigated O
. O

Patients O
' O
subjective O
perspective O
should O
be O
taken O
into O
account O
in O
this O
mainly O
palliative O
setting O
. O

Recruited O
were O
167 O
solid O
tumor O
children O
patients O
at O
Department O
of O
Tumor O
, O
Beijing O
Children O
's O
Hospital O
. O

Therefore O
, O
we O
compared O
the O
effect O
of O
the O
two O
therapies O
on O
fatigue O
in O
a O
randomised O
controlled O
study O
. O

Gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
APC O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
particularly O
important O
. O

We O
evaluated O
thalidomide O
, O
an O
anti-angiogenic O
agent O
, O
when O
combined O
with O
chemotherapy O
and O
as O
maintenance O
treatment O
. O

Change O
in O
peak O
cardiovascular O
fitness O
mediated O
the O
change O
in O
patient-rated O
physical O
functioning O
. O

By O
the O
criterion O
of O
an O
80 O
% O
prostate-specific O
antigen O
reduction O
maintained O
for O
at O
least O
8 O
weeks O
, O
11 O
( O
30 O
% O
) O
of O
37 O
patients O
in O
the O
TEE O
arm O
responded O
, O
whereas O
11 O
( O
32 O
% O
) O
of O
34 O
assigned O
to O
KA/VE O
responded O
. O

The O
main O
outcome O
measures O
were O
the O
unmet O
supportive O
care O
needs O
, O
health O
service O
utilization O
, O
and O
quality O
of O
life O
at O
1 O
, O
3 O
, O
and O
6 O
months O
postdischarge O
. O

Pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
Common O
Toxicity O
Criteria O
grade O
< O
1 O
) O
. O

Patients O
with O
stage O
III O
or O
IV O
cancer O
( O
N O
= O
120 O
) O
were O
randomly O
assigned O
to O
seven O
sessions O
of O
either O
IMCP O
or O
therapeutic O
massage O
( O
TM O
) O
. O

The O
primary O
end O
point O
was O
the O
difference O
in O
total O
liver O
volume O
, O
measured O
by O
computerized O
tomography O
at O
weeks O
0 O
and O
24 O
. O

To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT-I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

Overall O
urinary O
morbidity O
was O
worst O
at O
1 O
month O
after O
the O
implant O
. O

The O
trial O
was O
prematurely O
closed O
during O
recruitment O
, O
after O
a O
median O
follow-up O
of O
11.9 O
months O
( O
interquartile O
range O
7.1-19.6 O
, O
total O
6498 O
women O
years O
) O
in O
those O
enrolled O
, O
after O
the O
publication O
of O
early O
results O
from O
the O
women O
's O
health O
initiative O
study O
. O

In O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
, O
407 O
melanoma O
patients O
in O
stage O
IIA O
( O
301 O
patients O
) O
and O
IIB O
( O
106 O
patients O
) O
were O
randomly O
assigned O
to O
either O
IFNalpha O
and O
isotretinoin O
( O
isotretinoin O
group O
";" O
206 O
patients O
) O
or O
IFNalpha O
and O
placebo O
( O
placebo O
group O
";" O
201 O
patients O
) O
after O
excision O
of O
the O
primary O
tumor O
. O

This O
phase O
III O
trial O
was O
conducted O
to O
test O
whether O
the O
novel O
vascular O
disrupting O
agent O
ASA404 O
( O
vadimezan O
) O
, O
when O
combined O
with O
first-line O
platinum-based O
chemotherapy O
, O
improves O
survival O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
versus O
chemotherapy O
alone O
. O

Fifty O
patients O
were O
randomized O
";" O
30 O
patients O
received O
epoetin O
beta O
30,000 O
IU O
once O
weekly O
and O
20 O
received O
20,000 O
IU O
once O
weekly O
. O

